[COMPANY_001] Research and Development
LMB763 (nidufexor)
Clinical Trial Protocol CLMB763X2202 / [STUDY_ID_REMOVED]
A randomized patient -and-physician blinded, 
placebo -controlled, 24 -week study
 to assess the safety , 
tolerability and efficacy of LMB763 in patients w ith diabetic 
nephropathy
Document type: Amended Protocol Version
EUDRACT number: 2018 -002491 -40
Version number: 03 (Clean )
Clinical Trial Phase: II
Release date: 27-Oct-2020
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
[COMPANY_001] Confidential Page 2
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  procedures. Note: The SOM will not be a part of the Clinical Study  Report.
[COMPANY_001] Confidential Page 3
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Table of contents
Site Operations Manual (SOM)........................................................................................... [ADDRESS_1020626] of abbreviations ............................................................................................................ 8
Glossary  of terms ............................................................................................................... 11
Protocol summary .............................................................................................................. 19
1Introduction ....................................................................................................................... 23
1.1 Background ............................................................................................................ 23
1.1.5
Clinical Data.......................................................................................... 26
1.1.6 Human Safet y and Tolerability  Data ..................................................... 26
1.1.7 Human Pharmacokinetic Data ............................................................... 26
1.1.8 Human Pharmacod ynamic Data ............................................................ 27
1.2 Purpose .................................................................................................................. 27
2Objectives and endpoints ................................................................................................... 27
3Study  design ...................................................................................................................... 28
4Rationale ................................ ................................ ................................ ............................ 30
4.1 Rationale for stud y design .....................................................................................30
4.1.1 Rationale for choice of background therap y
.........................................30
4.2
Rationale for dose/regimen and duration of treatment .......................................... 31
4.3 Rationale for choice o f control drugs (comparator/placebo) or combination 
drugs ...................................................................................................................... 31
4.4 Purpose and timing of interim anal yses/design adaptations .................................. 31
4.5 Risks and benefits .................................................................................................. 31
4.5.1 Blood sample volume ............................................................................ 33
5Population ................................ ................................ ................................ .......................... 33
5.1 Inclusion criteria .................................................................................................... 34
5.2 Exclusion criteria ................................................................................................... 34
6Treatment ................................ ................................ ................................ ........................... 37
Commercially Confidential Information (CCI)
Commercially Confidential Information
[COMPANY_001] Confidential Page 4
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
6.1 Study  treatment ................................ ................................ ................................ ......37
6.1.1 Investigational and control drugs .......................................................... 38
6.1.2 Additional study  treatments .................................................................. 38
6.1.3 Treatment arms/group ........................................................................... 38
6.2 Other treatment(s) .................................................................................................. 39
6.2.1 Concomitant therap y
............................................................................. 39
6.2.2
Prohibited medication ........................................................................... 39
6.2.3 Restriction for study  patients ................................................................ 41
6.3 Patient numbering, treatment assignment, randomization ..................................... 42
6.3.1
Patient numbering ................................................................................. 42
6.3.2 Treatment assignment, randomization .................................................. 42
6.4 Treatment blinding ................................................................................................. 42
6.4.1 Treatment blinding -study  staff ............................................................ 42
6.4.2 Treatment blinding -sponsor staff ........................................................ 43
6.5
Dose escalation and dose modification.................................................................. 44
6.6 Additional treatment guidance ............................................................................... 45
6.6.1 Treatment compliance ........................................................................... 45
6.6.2 Recommended treatment of adverse events .......................................... 45
6.6.3 Emergency  breaking of assigned treatment code .................................. 46
6.7 Preparation and dispensation ................................................................................. 46
7Informed consent procedure s
............................................................................................ 47
8
Visit schedule and assessments ......................................................................................... 48
8.1 Screening ............................................................................................................... 52
8.1.1 Information to be collected on screening failures ................................. 52
8.2 Patient demographics/other baseline characteristics ............................................. [ADDRESS_1020627], Drug screen ...................................................................... 52
8.3 Efficacy  and Pharmacody namics ................................ ................................ ........... 52
8.3.1 Renal function assessments, markers of diabetic nephropath y............. 52
8.3.2 Type 2 diabetes measures ...................................................................... 53
8.3.3 Appropriateness of efficacy  assessments .............................................. 53
8.4 Safety  and Tolerab ility.......................................................................................... 53
8.4.1 Physical examination ............................................................................ 53
8.4.2 Vital signs .............................................................................................. 53
8.4.3 Laboratory  evaluations .......................................................................... 54
8.4.4 Electrocardiogram (ECG) ..................................................................... 55
8.4.5 Pregnancy  and assessments of fertility ................................................. 55
[COMPANY_001] Confidential Page 5
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
8.4.6 Appropriateness of safet y measurements .............................................. 55
8.5
Additional assessments.......................................................................................... 55
8.5.1 Clinical Outcome A ssessment - Visual Analog Scale (VAS) ............... [ADDRESS_1020628] -study  treatment .......................................................... 61
10Safety  monitoring and reporting ................................ ................................ ........................ 62
10.1 Definition of adverse events and reporting requirements ...................................... 62
10.1.1 Adverse events ...................................................................................... 62
10.1.2 Serious adverse events .......................................................................... 64
10.1.3 SAE reporting
........................................................................................ 65
10.1.4 Pregnancy  reporting .............................................................................. 66
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 66
10.2 Additional Safety  Monitorin g
................................................................................ 67
10.2.1 Liver safety  monitoring ......................................................................... 67
10.2.2 Renal safet y monitoring ........................................................................ 68
10.2.3 Fat soluble vitamin deficiency ..............................................................68
11Data Collection and Database management ...................................................................... 69
11.1
Data collection....................................................................................................... 69
11.2 Database management and quality  control ............................................................ 69
11.3 Site monitoring ...................................................................................................... 70
12Data analy sis and statistical methods ................................ ................................ ................ 70
12.1 Analy sis sets .......................................................................................................... 71
12.2
Patient demographics and other baseline characteristics....................................... 71
12.3 Treatments ............................................................................................................. 71
12.4 Analy sis of the primary  endpoint(s) ...................................................................... 71
12.4.1 Definition of primary  endpoint(s) ......................................................... 71
12.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 71
12.4.3 Handling of missing values/ce nsoring/discontinuations ....................... 73
12.4.4 Sensitivity  and Supportive anal yses...................................................... 73
Commercially Confidential Information
[COMPANY_001] Confidential Page 6
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
12.5 Analy sis of secondary  endpoints ................................ ................................ ........... 73
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s) .................................... 73
12.5.2 Pharmacokinetics .................................................................................. 73
12.5.5 PK/PD relationships .............................................................................. 74
12.5.6 Patient reported outc omes ..................................................................... 74
12.7 Interim anal yses..................................................................................................... 75
12.8
Sample size calculation.......................................................................................... 75
12.8.1 Primary  endpoint(s) ............................................................................... 75
13Ethical considerations and administrative procedures ...................................................... 76
13.1 Regulatory
 and ethical compliance ........................................................................ 76
13.2 Responsibilities of the investigator and IRB/ IEC.................................................. 76
13.3 Publication of study  protocol and results ............................................................... 77
13.4 Quality  Control and Quality  Assurance ................................................................. 77
14Protocol adherence ............................................................................................................ 77
14.1 Protocol Amendmen ts........................................................................................... 78
15References ................................ ................................ ................................ ......................... 79
16Appendices ........................................................................................................................ 81
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 81
16.2 Appendix 2: L iver event and Laboratory  trigger Definitions and Follow
-up 
Requirements ......................................................................................................... 82
16.3
Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow -up...... [ADDRESS_1020629] 1 month prior to 
randomization ................................ ................................ ........................ 41
Table 6-4 Blinding and unblinding plan................................................................ 44
Table 8
-1 Assessment Schedule ............................................................................ 48
Table 10
-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ................................ ................................ ......................... 67
Table 16-1 Liver Event and Laboratory  Trigger Definitions ................................ ..82
Table 16-2 Follow Up Requirements for L iver Events and Laboratory  Triggers ...83
Table 16-3 Specific Renal Alert Criteria and Actions ................................ ............. 85
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 7
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
List of figures
Figure 3 -1 LMB763X2202 stud y design ................................................................ 30
Commercially Confidential Information
[COMPANY_001] Confidential Page 8
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
List of abbreviations
ACEI angiotensin converting enzy me inhibitor
ADA/EASD American Diabetes Association / European Association for the Study of Diabetes
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analysis of covariance
ANIT alpha -naphthyl -isothioc yanate
aPTT activated Partial Thromboplastin Time
ARB angiotensin receptor blocker
AST aspartate aminotransferase
BCRP Breast cancer resistance protein, a member of the ATP-binding cassette 
transporters
BMI Body Mass Index
BUN blood urea nitrogen
CFR U.S. Code of Federal Regulations
CK creatine kinase
CKD -EPI [INVESTIGATOR_656954]&PS Chief Medical Office & Patient Safety
CNS Central nervous sy stem
CPK Creatine phosphokinase
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CTC Common Toxicity Criteria
CTCAE Common terminology criteria for adverse events
CV coefficient of variation
CYP Cytochrome P450 enzy me (i.e., CYP2C8, CYP2C9, CYP1A2, CYP2A6, CYP2D6, 
CYP2E1, CYP3A4/5)
ECG Electrocardiogram
EDC Electronic Data Capture
EDD estimated date of deliver y
eGFR Estimated glomerular filtration rate
eSAE Electronic Serious Adverse Event
eSource Electronic Source
FDA Food and Drug Administration
GCP Good Clinical Practice
GLP Good laborator y practice
GLP-1 Glucagon -like peptide -1
h hour
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 9
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
HbA1c Glycated haemoglobin
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
hCG Human chorionic gonadotropin
HCV Hepatitis C virus
HDL high-density lipoprotein
HDL-C High density lipoprotein cholesterol
HIV human immunodeficiency virus
i.v. intravenous
IB Investigator Brochure
ICF Informed Consent Form
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IL-[ADDRESS_1020630]
IRT Interactive Response Technology
KDIGO Kidney Disease: Improving Global Outcomes guidelines
LDH lactate dehy drogenase
LDL Low density lipoprotein
LDL-C Low density lipoprotein cholesterol
LFT Liver function test
LLN lower limit of normal
LP(a) lipoprotein (a)
LQT724 acyl glucuronide metabolite of LMB763 (nidufexor)
MCP -[ADDRESS_1020631] Modification of Diet in Renal Disease (equation for estimating eGFR)
MedDRA Medical dictionary for regulatory activities
mg milligram (s)
mL milliliter(s)
mm Hg millimeters of mercury
NAFLD Non-alcoholic fatty  liver disease
NASH Non-alcoholic steatohepatitis
NCDS [COMPANY_001] Clinical Data Standards
NOAEL No observed adverse effect level
NOVDD [COMPANY_001] Data Dictionar y
NSAID Non-steroidal anti -inflammatory drug
p.o. oral
PBC Primary biliar y cholangitis
PD pharmacodynamic(s)
Commercially Confidential Information
[COMPANY_001] Confidential Page 10
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
PK pharmacokinetic(s)
POC proof of concept
PSC Primary sclerosing cholangitis
PT prothrombin time
QMS qualit y managem ent system
QTcF QTc Fridericia correction formula
RAS renin- angiotensin system
RBC red blood cell(s)
SAD/MAD Single -ascending dose/multiple- ascending dose
SAE serious adverse event
sCR serum creatinine
SD standard deviation
SGLT -[ADDRESS_1020632] decapentaplegic homolog 3 also known as SMAD family memb er 
3
SOM Site Operations Manual
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
TBL total bilirubin
TD Study Treatment Discontinuation
UACR Urinar y album in to creatinine ratio
UDP Uridine 5'-diphospho -glucuronosyltransferase (UGT)
UGT1A1 UDP glucuronosyltransferase 1A1
UGT1A3 UDP glucuronosyltransferase 1A3
ULN upper limit of normal
ULQ upper limit of quantification
VAS Visual Analog Scale
WBC white blood cell(s)
WHO World Health Organization
WoC Withdrawal of Consent
WTH Waist-to-hip ratio
γGT or GGT γ-glutam yl transferase - or-Gamma -glutam yl transferase
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 11
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_37214] A specific group of patient s fulfilling certain criteria
Control drug Any drug(s) (an active drug or an inactive drug, such as a placebo) which is 
used as a comparator to the investigational drug being tested in the trial
Dosage Dose of the study treatment given to the patient in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study data 
using data collection s ystems, such as Web-based applications, interactive 
voice r esponse systems and clinical laboratory interfaces. 
EDC includes the use of Electronic Case Report Forms (eCRFs) which are 
used to capture data transcribed from paper source forms used at the point of 
care.
Epoch Interval of time in the planned conduct o f a study. An epoch is associated with 
a purpose (e.g. screening, randomization, treatment, follow -up) which applies 
across all arms of a study.
Enrollment Point/time of patient entry into the study at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)
eSource eSource Direct Data Entry (DDE) refers to the capture of clinical study data 
electronically, at the point of care. eSource combines source documents and 
case report forms (eCRFs) into on e application, allowing for the real time 
collection of clinical trial information to sponsors and other oversight 
authorities, as appropriate.
Healthy volunteer A person with no known significant health problems who volunteers to be a 
study participant 
Investigational 
drugThe study drug whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and Directive 2001/20/EC and is 
synony mous with “investigational new drug,” "Investigational Medicinal 
Product," or “test substance”
LMB763 Investigational [COMPANY_001] compound (nidufexor) to be studied in this protocol
Medication pack 
numberA unique identifier on the label of each drug package in studies that dispense 
study treatment using an IRT sy stem
Mobile hea lthcare 
professionalA qualified healthcare professional, such as a Nurse or Phlebotomist, who 
performs certain protocol procedures for the participant in a remote location 
such as a participant’s home.
Nidufexor Investigational [COMPANY_001] compound (LMB763) to be studied in this protocol
Part A single component of a study, which contains different objectives or 
populations within that single study. Common parts within a study are a single 
dose part and a multiple dose part, or a part in patients with establ ished 
disease and in those with newly diagnosed disease.
Patient An individual with the condition of interest
Personal Data Patient information collected by [CONTACT_221963]. This data includes patient identifier 
information, study information and biological samples.
Randomization 
numberA unique identifier assigned to each randomized patient, corresponding to a 
specific treatment arm assignment
Remote Alocation that is not the inves tigative site where the investigator will conduct 
the trial and where source data will be maintained, but is for example the 
participant’s home or another appropriate location
[COMPANY_001] Confidential Page 12
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Run in Failure A patient who is screened but not randomized/treated after the run-in period 
(where run -in period requires adjustment to patient’s medications or other 
intervention)
Screen Failure A patient who is screened but is not treated or randomized
Source 
Data/DocumentSource data refers to the initial record, document, or p rimary  location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource
Study treatment Any drug or combination of drugs administered to the study participants as 
part of the req uired study procedures; includes investigational drug(s), 
control(s) or background therapy
Study treatment 
discontinuationWhen the patient permanently stops taking study treatment prior to the defined 
study treatment completion date
Patient A trial participant (can be a healthy volunteer or a patient)
Patient number A unique number assigned to each patient upon signing the informed consent. 
This number is the definitive, unique identifier for the patient and should be 
used to identify the patient throughout the study for all data collected, sample 
labels, etc.
Treatment number A unique identifier assigned in non- randomized studies to each dosed patient, 
corresponding to a specific treatment arm 
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested in 
the study
Withdrawal of 
study consentWithdrawal of consent from the study occurs only when a patient does not 
want to participate in the study any longe r, and does not allow any further 
collection of personal data
[COMPANY_001] Confidential Page 13
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 14
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 15
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 16
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 17
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 18
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 19
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Protocol summary
Protocol number CLMB763X2202
Full Title A randomized patient -and-physician blinded, placebo -controlled, 24-week 
study to assess the safety, tolerabilit y and efficacy  of nidufexor in patients 
with diabetic nephropathy
Brief title A study of the safety and efficacy  of nidufexor in patien ts with diabetic 
kidney disease
Sponsor and 
Clinical Phase[COMPANY_001]
Phase [ADDRESS_1020633] of care (angiotensin converting enzy me inhibitor or angiotensin 
receptor blocker). This non-confirmatory Phase 2 study  is designed to 
determine the safety , tolerability, efficacy, pharmacokinetics and 
pharmacodynamics of nidufexor in combination with dose of angiotensin 
converting enzy me inhibitor (ACEI) or angiotensin receptor blocker (ARB)
that is the standard of care as judged by [CONTACT_978] [INVESTIGATOR_11637]-Iin patients with 
type 2 diabetes and nephropathy.
Primary Objective(s) To compare the effect of nidufexor to placebo on albuminuria in patients 
with diabetic nephropathy already receiving treatment with an angiotensin 
converting enzy me inhibitor (ACEI) or angiotensin receptor blocker (ARB) 
as measured by [CONTACT_746198] [ADDRESS_1020634] of nidufexor on anthropometric assessments 
(weight, body mass index, and waist -to-hip ratio)
To determine the effect of nidufexor on lipi[INVESTIGATOR_746188] a fasting 
lipid profile
[COMPANY_001] Confidential Page 20
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Study design A non-confirmatory, multicenter, patient and investigator blinded, 
randomized, placebo -controlled, fixed -dose, proof -of-concept trial 
assessing nidufexor vs. placebo. The study  consists of a 30- day 
(Day -30 to Day-1) Screening period, followed by a 24-week Treatment 
Period (Day s 1 through 168), at which point End of Study (EOS) 
assessments will occur on Day 169. PK profiling (up to [ADDRESS_1020635]-dose) 
will be done on Day 1 and Day 14. 
Population Approximately 116 men and women, between 18 and 75 years of age, 
with type 2 diabetes and diabetic nephropathy will be enrolled.
Key Inclusion 
criteriaWritten informed consent must be obtai ned before any assessment
is performed
Male and female patients ≥ 18 years and ≤ 75 years (at the time of
the screening visit)
Diagnosis of type [ADDRESS_1020636] 6
months prior to screening, as determined by [CONTACT_746199]
Diabetic nephropathy as evidenced by [CONTACT_746200] -Cr ratio
(UACR) ≥ 300 mg/g Cr while receiving a dose of angiotensin
converting enzy me inhibitor (ACEI) or angiotensin receptor blocker
(ARB) that is the standard of care as judged by [CONTACT_978] [INVESTIGATOR_11637] -I
Dose of either (ACEI or ARB) that is standard of care as judged
by [CONTACT_978] [INVESTIGATOR_11637] -Imust also be stable, defined as < 25% dose
change over at least 4 weeks prior to screening.
Key Exclusion 
criteri a
History of T ype 1 diabetes mellitus, or uncontrolled type 2 diabete s
mellitus as evidenced by [CONTACT_13505]1c > 11%
The presence of kidney disease, other than diabetic nephropathy;
severe renal impairment manifesting as serum creatinine -based
eGFR <30 mL/min/1.73 m2at scre ening, as determined by [CONTACT_746201] -EPI [INVESTIGATOR_14420]; histor y of ren al transplant or planned renal
transplant during the study, histor y of: primary kidney disease,
including, but not limited to primary  glomerulonephritis, focal
segmental glomerulosclerosis, polycystic kidney disease, or
memb ranous nephropathy; secondar y kidney  disease other than
diabetic nephropathy, including but not limited to lupus nephritis,
obstructive uropathy, and renovascular disease; or acute renal
dialysis or acute kidney injury stage 2 or 3. as defined in the
Kidney Disease: Improving Global Outc omes [KDIGO] guidelines
Uncontrolled hypertension despi[INVESTIGATOR_746189] -hypertensive
therapy as e videnced by [CONTACT_141165] >150/[ADDRESS_1020637] as determined
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 21
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
by [CONTACT_746202] 3 measurements obtained over approximately 
15minutes while sitting
History or presence of liver disease including serum ALT or AST >1.[ADDRESS_1020638]; active Hepatitis B or Cvirus (HCV, HBV) infection (positive
HBV surface antigen (HBsAg) test excludes a patient ); primary  biliary
cholangitis (PBC); primary sclerosing cholangitis (PSC); alcoholic
liver disease; cirrhosis; definite autoimmune liver disease or overlap
hepatitis; suspected or confirmed Gilbert's syndrome; known bile duct
obstruction; suspected or proven liver cancer; liver transplantation or
current placement on a liver transplant list ( Note: Patients with NASH
or NAFLD are not excluded, if their transaminase levels comply with
exclusion criterion) ; or clinical evidence of hepatic decompensation or
severe liver impairm ent as defined by [CONTACT_746203]: serum albumin <L LN; Total Bilirubin >120%
of ULN; alkaline phosphatase >300 U/L; history of esop hageal
varices, ascites or hepatic encephalopathy; splenomegaly; platelet
count <LLN; or prior or planned (during the study  period) bariatric
surgery ( e.g., gastroplasty, roux -en-Y gastric by[CONTACT_6476]).
History or current diagnosis of ECG abnormalities indicating
significant risk of safety for patients participating in the study
Study treatment 25 mg nidufexor capsules 
matching placebo capsules
Efficacy 
assessmentsUrine albumin -creatinine ratio (UACR) at serial time points, as
specified in the Assessment S chedule
24-hour urinary albumin at baseline and end of study
Pharmacodynamic 
AssessmentsEstimated glomerular filtration rate (eGFR), as determined by [CONTACT_597020][INVESTIGATOR_10444] (CKD -
EPI) equation
Free water clearance
Weight
BMI
Waist-to-hip (W TH) ratio
Fasting lipid profile
Pharmacokinetic 
AssessmentsCmax
Tmax
AUClast
Key Safety 
Assessmentsvital signs
physical examination
laborator y markers in blood and urine
ECG
adverse event monitoring
Visual analog scale for itch
CCI
CCICCI
[COMPANY_001] Confidential Page 22
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Other A ssessments
Data A nalysis The primary objective of this study is to assess the safety and tolerability 
of nidufexor as well as the efficacy  of nidufexor on albuminu ria in patients 
with diabetic nephropathy during 24 weeks of treatment. Forefficacy 
evaluation, log-transformed ratios to baseline UACR and 24- hour urine 
albumin excretion at Week 24 are the primary  endpoints. A repeated 
measures Analy sis of Covariance (ANCOVA) will be performed for 
log-transformed ratio to baseline UACR measured at each visit. Similarly,
an ANCOVA with treatment as the classification factor and log-
transformed baseline as the cova riate will be conducted for 
log-transformed ratio to baseli ne 24 -hour urine albumin excretion.
For analytical purposes, all safety data, including laboratory 
measurements, vital signs, adverse events, ECG, are considered primary 
endpoints. Safety and tolerability data will be summarized. Formal 
statistical analy sis will not be performed on the safety and tolerability  data.
Log-transformed ratio to baseline for eGFR, free water clearance, HbA1c 
and fasting lipid profiles (total cholesterol, HDL, LDL, triglycerides and 
Lp(a)) as well as change from baseline in weight , BMI and W TH ratio will 
be analyzed using the same repeated measures ANCOVA with baseline 
in lieu of log-transformed baseline as a covariate for change from baseline 
analysis.
Key Words Nidufexor , LMB763, Farnesoid X receptor, placebo -controlled, 
multicenter, patient and investigator blinded, randomized, placebo -
controlled, fixed -dose, proof -of-concept trial, diabetic nephropathy, type 2 
diabetes, tolerability, safety, 24-hr urinar y albumin, urinar y albumin to 
creatinine ratio (UACR), free water clearance, HbA1c, estimated 
glom erular filtration rate (eGFR), CKD -EPI, angiotensin receptor blocker 
(ARB), angiotensin converting enzy me inhibitor (ACEI), fasting lipid profile
Commercially Confidential Information
[COMPANY_001] Confidential Page 23
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
1 Introduction
1.1 Background
LMB763 (nidufexor) is a potent partial agonist of the bile acid receptor Farnesoid X Receptor 
(FXR). Proposed indications for nidufexor include non-alcoholic steatohepatitis (NASH), 
cholestatic and other hepatic disorders caused by [CONTACT_746204], and diabetic nephropathy .
In diabetic nephropathy , hypergly cemia, dy slipi[INVESTIGATOR_746190], resulting in endothelial and podocy te epi[INVESTIGATOR_24603] l injury . In the kidney , FXR 
isexpressed in the glomeruli and tubules (Marquardt et
al2017 , Zhang et al 2014). 
FXR agonism decreases markers 
of fibrosis, oxidative stress, inflammation and cell death in 
rodent models of kidney disease. Specificall y, FXR agonism decreases SMAD3 in a mouse 
renal fibrosis model (Zhao et
al2016), and decreases MCP - 1, IL-6, H 2O2and markers of 
apoptosis in a mouse ischemia- reperfusion renal injury  model (Gaiet al2016). 
Furthermore, FXR agonism in uninephrectomized obese mice reduces albuminuria
 and urinary 
H2O2, and improves renal histology , oxidative stress, lipid accumulation and mitochondrial 
function (Gaiet al 2016, Gaiet al 2017 ). In this same model, nidufexor in combination with 
angiotensin receptor blockade (ARB) reduced albuminuria better than either nidufexor or ARB 
alone.
Diabetic nephropathy  is the single most common cause of chronic kidney  disease in the [LOCATION_003], 
affecting approximately 16 million Americans. Diabetic nephropathy  is a global health 
problem: a cross sectional study  among over 32,000 ty pe 2 diabetic patients from 33 countries 
revealed that the prevalence of micro -and macroalbuminuria is 38.8% and 9.8%, respectivel y 
(Gheith et al 2016). Other analy ses suggest that diabetic nephr opath y affects approximately 
18million people in India (Pradeepa andMohan 2017), and approximately  44 million people 
in China ( Maet
al2018).
The standard of care, primarily angiotensin converting enz yme inhibitor (ACEI ) or angiotensin 
receptor blocker (ARB), is focused on delaying rather than prev
enting progression to end stage 
renal disease (Umanath andLewis 2018). Nidufexor addresses fibrosis, oxidative stress, 
inflammation and cell death, and therefore has the potential to improve the management of 
diabetic kidn ey disease when added to the standard of care ACEI or ARB.
The most relevant data for the present study are summar ized in the sections below. For detailed 
information, please refer to the I nvestigator's Brochure.
Commercially Confidential Information
[COMPANY_001] Confidential Page 24
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 25
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 26
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
1.1.[ADDRESS_1020639] been completed for nidufexor: a SAD/MAD safety/tolerabilit y study 
in health y subjects and a proof -of concept study  in patients with biops y-proven or phenot ypic 
NASH .(see Protocol Section 1.1.6, and the Investigator's Brochure for additional information).
1.1.6 Human Safety  and Tolerability  Data
Study  
CLMB763X2201 was a randomized, patient -and investigator -blinded, placebo
-controlled, 
multicenter study  to assess the safety , tolerabilit y, pharmacokinetics and efficacy  of nidufexor 
in patients with biopsy -proven or phenoty pic NASH. A total of 121 patients were randomized 
of which 81 subjects received nidufexor at starting doses of 100 mg (Cohort 1; N=37) o r 50mg 
(Cohort 2; N=44). The most commonly  reported AE was itch. Discontinuation due to AE was
most frequently  in the 100mg nidufexor group . Itch was considered a tolerability  but not safet y 
finding, and overall nidufexor was considered generall y well to lerated at 50 mg and 100 mg in 
patients with NASH.
Further details are available in the I nvestigator’s Brochure.
1.1.7 Human Pharmacokinetic Data
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 27
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
1.1.8 Human Pharmacodynamic Data
1.2 Purpose
The purpose of this proof -of-concept study  is to determine whether LMB763 (nidufexor), an 
FXR agonist, warrants continued clinical development for the treatment of diabetic nephropathy .
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary objective(s) Endpoint(s) for primary objective(s)
To compare the effect of nidufexor to 
placebo on albuminuria in patients with 
diabetic nephropathy already recei ving 
treatment with ACEI or ARBUrine albumin -creatinine ratio (UACR) at serial time 
points, as specified in the Assessment Schedule
24-hour urinary albumin at baseline and end of study
To assess the safety  and tolerability of 
nidufexorSafety e ndpoints including:
vital signs
physical examination
laborator y measurements
ECG parameters
adverse events
Secondary objective(s) Endpoint(s) for secondary objective(s)
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 28
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Objective(s) Endpoint(s)
To determine the effect of nidufexor on 
renal filtration functionEstimated glomerular filtration rate (eGFR), as 
determined by [CONTACT_55389][INVESTIGATOR_10444] (CKD -EPI) equation 
(Leve yand Stevens 2010 )
To assess the pharmacokinetic properties 
of nidufexor on day [ADDRESS_1020640]-to-hip (W TH) ratio
To determine the effect of nidufexor on 
lipi[INVESTIGATOR_746191], including lipoprotein (a) [Lp(a)]
[ADDRESS_1020641] of care (optimal tolerated doses of ARB or 
ACEI) for diabe tic nephropathy  due to type 2 diabetes. The study  consists of a 30-day (Day -
30 to Day-1) Screening Period, followed by a24-week Treatment Period (Day s 1 through 168), 
Commercially Confidential Information
[COMPANY_001] Confidential Page 29
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
at which point End of Study  (EOS) assessments will occur on Day 169. All study  visit 
assessments will occur pre-dose, starting 
on Day 1 of the therapeutic perio d. PK profiling (upto 
[ADDRESS_1020642]-dose) will be done on Day [ADDRESS_1020643] will occur 
approximately  28 days after discontinuin g study  treatment (Day  197). 
Patients will be provided with a supply  of study  medication for self-administration during the 
treatment period. Detailed instruc tions for taking study  treatment will be provid
ed in the 
SiteOperations Manual (SOM). Patients will continue to take study  medication  for 
24 weeks (Day  1-168), as instructed by [CONTACT_093], and study  assessments will be 
performed once monthl y until the EOS 
visit (Day  169).
At the investigator’s direction and based on benefit -risk considerations of the participant’s 
clinical condition, qualifying patients may be offered the option to have certain clinical trial 
procedures according to Table 8-1performed at a remote location. Procedures will be performed 
remotely  under the oversight of the investigator, who retains accountabilit
y for oversight and 
all efficacy  and safety  decisions with delegation of tasks to mobile health professionals (i.e.,
research nurses). The remote procedures will be offered in certain countries and sites as 
determined by [CONTACT_131337]. The mobile research nurses 
will be provided by  a third -party vendor sourced by [CONTACT_5343]. Where a site wishes to use their 
own mobile health professionals that are not provided by [CONTACT_5343], this must be agreed with 
[COMPANY_001] prior to implement
ation.
The study  design scheme appears below. On visit day s, study  medication will be administered 
by [CONTACT_746205] . Each visit during the treatment and follow -up periods will have 
an allowable window of +/- [ADDRESS_1020644] clinical 
laboratory  evaluations (hemat ology , blood chemistry , urinal ysis), adverse event and serious 
adverse event monitoring.
Refer to the Assessment Schedule for details of safety , PK and PD assessments.
Commercially Confidential Information
CCI
[COMPANY_001] Confidential Page 30
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Figure 3-1 LMB763X2202 study  design
Patients will be randomized in a 1:[ADDRESS_1020645] of nidufexor 
on urinary  albumin excretion over a 24-week treatment period, in patients with 
macroalbuminuric diabetic nephropath y on ACEI or ARB therapy . Change in albuminur ia 
(UACR and 24- hour urine albumin excretion) and annualized rate of change in eGFR over the 
24-week treatment period are the primary  and secondary  endpoints, respectively . These two
parameters comprise the current gold standard (Levey et al2015) for assessing stage and
progression of proteinuric chronic kidney  diseases such as diabetic nephropathy  secondary  to
Type 2 Diabetes.
Patient -and i nvestigator -
blinded study : Blinding of patients and investigators allows for
anunbiased assessment of patient readouts such as adverse events.
Randomized: Randomization decreases the chance of an imbalance in patient
characteristics between groups, thereb y facilitating an unbiased assessment of safet y,
tolerability , and efficacy .
Placebo -controlled: This is critical to establish that any  safet y, tolerability, or efficacy
outcome can be attributed to the study  drug as opposed to an effect of study procedures.
Fixed- dose: This study  will not involve dose adjustments unless needed due to tolerability
issues (see Section 6.5
). The dose selection rationale is described in the next section.
4.1.1 Rationale for choice of background therapy
Pharmacologic blockade of the renin -angiotensin sy stem (RAS) with ACEI  or ARB slows and 
delay s progressive decline in kidney  function in proteinuric diseases such as diabetic 
nephropath y. RAS blockade benefits proteinuric kidney  disease via several mechanisms, 
including reduction in intraglomerular pressure, impr oved blood pressure control, and possibly 
anti-fibrotic actions. RAS blockade is therefore standard of care for many proteinuric kidney 
diseases, aiming to reduce urine protein excretion as the key pharmacody namic 
marker 
(Umanath andLewis 2018 ).
CCI CCI
CCI
[COMPANY_001] Confidential Page 31
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
4.2 Rationale for dose/regimen and duration of treatment
The CLMB763X2202 study  population is expected to have comparable PK to the 
CLMBX2201 population. 
The duration of the study  is based on (a) the high variability  typi[INVESTIGATOR_746192], and (b) the high variabilit y and slow rate of change in eGFR; the 24-week 
treatment period will allow more robust assessment of a potential anti-proteinuric effect 
(primary  endpoint) and potential slowing of eGFR decline (secondary  endpoint). Since both of 
these parameters demonstrate high intra-and inter-patient variability , repeated measures over 
[ADDRESS_1020646] potential tre atment effects.
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
ACEI  or ARB agents are currentl y prescribed to patients with type [ADDRESS_1020647] of 
care (ACEI or ARB).
4.4 Purpose and timing of int erim analy ses/design adaptations
4.5 Risks and benefits
Appropriate eligibility  criteria and specific dose-limiting toxicity  definitions, as well as specific 
dose modification and stoppi[INVESTIGATOR_004], are included in this protocol.
Commercially Confidential Information
Commercially Confidential InformationCommercially Conf idential Information
[COMPANY_001] Confidential Page 32
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Women of child bearing potential and sexually  active males must be informed that taking the 
study  treatment may  involve unknown risks to the fetus if pregnancy  were to occur during the 
study , and agree that in order to participate in the study  they must adhere to the contraception 
requirements outlined in the exclusion criteria. If there is any  question that the patient will not 
reliably  comply , they  should not be entered or continue in the study .
As well asthe risks and potential risks described in the Investigator's Brochure, there may be 
unknown risks o f nidufexor , which may be serious and unforeseen. The risk to patients in this 
trial may  be minimized by [CONTACT_271446], as well 
as close clinical monitoring, stoppi[INVESTIGATOR_004], and periodic review of safet y data .
Refer to the current section of the nidufexor IB for latest information on identified and potential 
adverse effects.
A high level summary  of risks are provided below.
In the CLMB763X2201 study  (NASH patients), adverse events 
related to increased ALT were reported more commonly in placebo (4/40; 10%) than in groups 
receiving 50mg nidufexor (2/44; 4.5%) or 100 mg nidufexor (1/37; 2.7%); adverse events 
related to increased AST were reported in 1 (2.5%) patients receiving placebo, and 1 (2.3%) 
and 4 (10.8%) patients receiving [ADDRESS_1020648].
. Serum lipi[INVESTIGATOR_746193] .
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 33
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Refer to Section [ADDRESS_1020649] version of nidufexor Investigator's Brochure for detailed 
information on identified and potential adverse effects.
In addition, investigators will be advised to manage glycemic control for all patie nts in a manner 
consistent with local treatment guidelines for type 2 diabetes. In the absence of local guidelines, 
investigators are referred to the joint ADA/EASD guidelines for the management of glucose 
control in patients with ty pe 2 diabetes ( Inzucchi et al 2015).
The assessment of the Benefit/Risk for the study  in the context of COVID -19 pandemic 
concluded the absence of additional 
risks for the study  population and/or related to the 
investigational medicinal produ ct.
4.5.1 Blood sample volume
A total blood volume of approximately  240 mL is planned to be collected over a period of 
approximately  32 weeks from each patient as part of the study . Additional samples may be 
required for safet y monitoring, which are not included in the noted estimate. This estimate 
includes approximate planned overdraw amounts required b y locally  available blood collection 
tubes. 
Timings of blood sample collections are outlined in the Assessment Schedule and a summar y 
blood log is provided in the Site Operations Manual (SOM). I nstructions for sample collection, 
processing, storage and shipment information may be found in the SOM and the central 
laboratory  manual.
See the Section
[IP_ADDRESS] on the u se of residual biological samples.
5 Population
The study  population will be comprised of male and female patients with diabetic nephropath y 
due to ty pe 2 diabetes.
Approximately  116 patients will be randomized in the study . Approximately  100patients are 
expected to complete the study .
Commercially Confidential Information
[COMPANY_001] Confidential Page 34
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
The investigator must ensure that all patients being considered for the study meet the followin g 
eligibility  criteria. No additional criteria should be applied by [CONTACT_093], in order that the 
study  populatio n will be representative of all eligible patients.
Patient selection is to be established by [CONTACT_548567]. 
Arelevant record (e.g.,checklist) of the eligibility  criteria must be stored with the source 
documentation.
Deviation from any entry criterion excludes a patient from enrol lment into the study . Details on 
re-screening are located in Section 8.1.
5.[ADDRESS_1020650] meet allof the following criteria:
1.Written informed consent must be obtained before any  assessment is performed
2. Male and female patients ≥ 18 y ears and ≤ 75 years (at the time of the scre ening visit) .
3.Diagnosis of t ype [ADDRESS_1020651] 6 months prior to
screening, as determined by  [CONTACT_746206] 2010
4.Diabetic nephropathy  as evidenced b y Urine albumin- Cr ratio (UACR) ≥ 300 mg/g Cr at
screening while receiving a dose of ACE -I or ARB that is the standard of care as judged
by [CONTACT_978] [INVESTIGATOR_11637] -I
Dose of ACE -I or ARB that is the standard of care as judged b y the PI [INVESTIGATOR_11637] -Imust
also be stable, defined as <25% dose change that occur redat least 4 weeks prior to
screening.
5.2 Exclusion criteria
Patient s meeting an y of the following criteria are not eligible for inclusion in this study .
3.History  of Ty pe 1 diabetes mellitus
4.Uncontrolled ty pe 2 diabetes mellitus as evidenced by  [CONTACT_13505]1c > 11% at screening
5.The presence of kidney  disease, other than diabetic nephropathy ,at screening including:
Primary  kidney  disease, including, but not limited to primary  glomerulonephritis,
focal segmental glomerulosclerosis, poly cystic kidney  disease, or membranous
nephropath y;
Secondary  kidney  disease, other than diabetic nephropathy , including but not limited
to lupus nephritis, obstructive uropath y, and renovascular disease;
History  of acute renal dialy sis or a cute kidney  injury  stage 2 or 3 as defined in the
Kidney  Disease: I mproving Global Outcomes [KDIGO] guidelines
(Okusa andDavenport 2014)
Commercially Confidential Information
[COMPANY_001] Confidential Page 35
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
6. Severe renal impairment manifesting as serum creati nine-based eGFR
<30mL/min/1.73 m2at screening, as determined by  [CONTACT_91019] -EPI [INVESTIGATOR_14420]
(Leve yandStevens 2010 )
7.History  of renal transplant or planned renal transplant during the study
8.Diagnostic or interventional procedure requiring any  potentiall y nephrotoxic contrast
agent within [ADDRESS_1020652] screening visit, or planned during the study
9.Uncontrolled h ypertension ( Whelton et al 2018), despi[INVESTIGATOR_746189] -hypertensive
therap y,as eviden ced by  [CONTACT_141165] >150/[ADDRESS_1020653] of 3 measurements obtained over approximately  15 minutes while sitting
10.History  or presence of liver disease at screening including:
Active Hepatitis B or C virus (HCV, HBV) infection
Note: A positive HBV surface antigen (HBsAg) test excludes a 
patient
Primary  biliary  cholangitis (PBC)
Primary  sclerosing cholangitis (PSC)
Alcoholic liver disease
Cirrhosis
Definite autoimmune liver disease or overlap hepatitis
Suspected or confirmed Gilbert's s yndrome
Known bile duct obstruction
Liver transplanta tion or current placement on a liver transplant list
Suspected or proven liver cancer
Note: Patients with NASH or NAFLD are not excluded, if their transaminase
levels comply with exclusion criterion [ADDRESS_1020654] >1.[ADDRESS_1020655] at screening.
12.Clinical evidence of hepatic decompensation or severe liver impairment as defined b y the
presence of an y of the following abnormalities at screening :
Serum albumin <LLN
Total Bilirubin >120% X ULN or Gilbert's s yndrome
Alkaline phosphatase >300U/L
History  of esopha geal varices, ascites or hepatic encephalopath y
Splenomegal y
Platelet count <LLN
Commercially Confidential Information
[COMPANY_001] Confidential Page 36
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
18.Receiving an y of the prohibited medications listed in Table 6-2,(e.g. UGT1A1 inhibitors,
herbal remedies that inhibit UGT1A1, non-selective UGT inhibitors, ACEI and ARB in
combination, direct renin inhibitors, SGL T2 inhibitors, GL P1-receptor agon ists)and
unable to switch to suitable alternatives at least [ADDRESS_1020656] study  dose indicating
significant risk of safet y forpatients participating in the study
22.Donation or loss of >400 mL  or more of blood within eight (8) weeks prior to initial
dosing, or longer if required b y local regulation
23.Known positivity  for Human I mmunodeficiency  Virus (HIV) infection
24.Women of childbea ringpotential, defined as all women physiologicall y capable of
becoming pregnant, unless they are using basic methods of contraception during dosing
ofstudy  treatment .
Basic contraception methods include:
Total abstinence (when this is in line with 
the preferred and usual lifest yle of the
patient). Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorect omy with or without
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment
Note: In case of oophorectomy alone, only when the reproductive status of the
woman has been confirmed by [CONTACT_104]
Male sterilization (at least 6 months prior to screening)
Note: For female patients on the study the vasectomized male partner should be
the sole partner for that patient
Barrier methods of contraception: condom or occlusive cap (e.g. , diaphragm or
cervical/vault caps ).
Use of oral (estrogen and progesterone), injected or implanted combined hormonal
methods of contraception or placement of an intrauterine device (IUD) or intrauterine
system (IUS), or other forms of hormonal contraception that have comparable
efficacy  (failure rate <1%), for example hormone vaginal ring or transdermal
hormone contraception
Note: In case of use of oral contraception, women should have been stable on the
same pi[INVESTIGATOR_6522] a minimum of 3 month s before taking study treatment
Commercially Confidential Information
[COMPANY_001] Confidential Page 37
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Women are considered post-menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor s ymptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ), total hy sterectom y or tubal ligation at least 
six weeks before taking study  treatment. In the case of oophorectomy  alone, only  when 
the reproductive status of the woman has been confirmed by  [CONTACT_430339].
25.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female
after conception and until the termination of gestation, confirmed by  a positive hCG
laboratory  test
Noadditional exclusions may be applied by [CONTACT_093] , in order to ensure that the study  
population will be representative of all eligible patients.
6 Treatment
6.1 Stud y treatment
Details on the requirements for storage an d management of study  treatment andinstructions to 
be followed for patient numbering, prescribing/dispensing and taking study  treatment are 
outlined in the SOM and on the medication label .
Instructions for administering study  treatment
On visit days, study  medication will be administered after an overnight fast of at least 6 h by 
[CONTACT_746205] . Medication will be administered with a half a glass (approximately 
120mL) of water in the morning. Each patient’s mouth must be checked to ensure that the 
medication was swallowed. Patients must be instructed not to chew the medication, but to 
swallow it whole.
Patients are encouraged to follow a similar routine for taking study treatment on non -visit day s.
However it is not essential for medication to be taken under fasted conditions.
Visit day s -All doses administered to the patient on visit day s will be recorded on the Dosage 
Form CRF.
Commercially Confidential Information
[COMPANY_001] Confidential Page 38
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Non-visit day s -Patients will be provided with individual diaries to record each administration 
of study  treatment on non -visit days. If a patient misses a dose at scheduled time +/-[ADDRESS_1020657] to hand over to all study  participants 
who receive a dose of study medication ( nidufexor or placebo), which will state that the subject 
is participating in a clinical study  and may  have received an investigational drug.
This emergency study card will also include the contact [CONTACT_746207]/Investigative Site. Designated study  staff will instruct study  participants to present this 
card to a medical care provider if they  have an y medical issues during the course of the stud y.
6.1.1 Investigational and control drugs
Table 6-1 Investigational and control drugs
Investigational/Control Drug
Investigational/ 
Control Drug
(Name [CONTACT_6673])Pharmaceutical 
Dosage FormRoute of 
Administ rationPackaging Sponsor 
(global or 
local)
LMB763 [ADDRESS_1020658] or other approved trained personnel. Study treatments are defined as:
 25 mg LMB763 capsules
 matching p lacebo capsules
[IP_ADDRESS] Decentralized Clinical Trial Model ( select US sites only )
The study  medication and all required clinical study  supplies will be distributed via direct -to-
participant shipment utilizing an extension of the IND for compliance purposes.
6.1.[ADDRESS_1020659] include either an angiotensin converting enzyme inhibitor (ACEI) or 
an angiotensin receptor blocker (ARB), as per the inclusion criteria. Use of dual 
renin -angiotensin system inhibitors (ACEI  + ARB) is prohibit ed.
6.1.3 Treatment arms/group
Patients will be assigned at Visit 101 to one of the following treatment arms in a ratio of 1:1.
Study  treatments are defined as:
CCI
CCICCI
[COMPANY_001] Confidential Page 39
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
LMB763  (  LMB763 25 mg capsules)
Placebo (  placebo capsules)
6.2 Other treatment(s)
6.2.1 Concomitan t therapy
Treatment other than study  treatment is permitted through the entire study  duration, if such 
treatment is not prohibited as defined in Section 6.2.2 .
Hormonal contraception is allowed during this study  (see Section 5.2).
All medications, procedures and significant non -drug therapi[INVESTIGATOR_014] (including physical therap y and  
blood transfusions) administered after the patient was enrolled into the study  must be recorded 
in the concomitant med ications / significant non
-drug therapi[INVESTIGATOR_638571].
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication.
If in doubt the investigator should contact [CONTACT_746208], or designee, 
before randomizing a patient or allowing a new medication to be started. If the patient is alread y 
enrolled, the investigator should contact [CONTACT_746208], or designee, 
to determine if the patient should continue pa rticipation in the study .
[IP_ADDRESS] Permitted concomitant therapy  requiring caution and/or action
Persistent Hyperglycemia: Investigators are advised to manage glycemic control for all patients 
in a manner consistent with local treatment guidelines for type 2 diabet es. In the absence of 
local guidelines, investigators are referred to the joint ADA/EASD guidelines for the 
management of glucose control in patients with ty pe 2 diabetes ( Inzucchi et al 2015).
Dose Adjustments: Nidufex or may moderatel y reduce the clearance of medications that are 
substrates of CYP2C8. Administration of nidufexor with pi[INVESTIGATOR_051], rosiglitazone, or 
glyburide (glibenclamide) could result in higher serum concentrations of these medications, 
thereb y increasing the potential for hy poglycemia. Frequent, regular fingerstick blood glucose 
monitoring is advisable during the treatment phase of this study , with subsequent dose 
adjustments of these medications as needed.
NSAIDs, COX -2s:Modest doses of non-steroidal anti-inflammatory  drugs (NSAIDs) or 
selective cycloox ygenase -
2 (COX -2) inhibitors may be used for a period not longer than 7 days.
6.2.2 Prohibited medication
Use of the treatments displayed in Table 6 -3are NOT allowed after the start of study treatment 
until the patient's final dose of oral stud y medication ( nidufexor or placebo).
Nidufexor is metabolized primarily  by [CONTACT_15924]1A1. There is a potential for inhibitors of UGT1A1 
to affect the clearance of nidufexor . There is also a potential that nidufexor will affect the 
disposition of medications that are substrates of CYP2C8.
CCI CCI
CCI
[COMPANY_001] Confidential Page 40
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Patients with known Gilbert’s syndrome and those taking concomitant medications and 
herbal remedies that inhibit UGT1A1 or are a profound CYP 2C8 substrate should be 
EXCLUDED from clinical trials of nidufexor until formal clinical drug -drug interaction 
studies have been performed.
Restricted Antihyperglycemic Medications: The SGL T-2 inhibitors (e.g. canagliflozin, 
dapagliflozin, empagliflozin) and GLP-1 recepto r agonists (e.g. exenatide, liraglutide, 
albiglutide, dulaglutide, semaglutide, lixisenatide) are prohibited m edications in this study . 
Alist of generic and trade names is provided in the SOM.
Table 6-2 Prohibited medication
Medication Prohibition period Action taken
Specific UGT1A1 inhibitors: e.g 
atazanavir, gemfibrozil, indinavir, 
itraconazole, ketoconazole, 
manidipi[INVESTIGATOR_050], and zafirlukastAny use from first 
drug intake to end-
of-study visitDiscontinue UGT1A1 inhibitor, if 
possible. Stop nidufexor . Check a 
random nidufexor level, noting time 
elapsed since last dose.
Herbal remedies inhibiting 
UGT1A1:e.g Silybum marianum 
(sylamarin, milk thistle) and 
Valeriana officinalis ( valerian)Any use from first 
drug intake to end -
of-study visitDiscontinue herbal remedy . Stop 
nidufexor and check a random nidufexor 
level, noting time elapsed since last 
dose.
Non-selective UGT inhibitors: e.g 
diclofenac, probenecid, valproic 
acidAny use from first 
drug intake to end -
of-study visitDiscontinue non -selective UGT 
inhibitors, if possible. Stop nidufexor 
and check a random nidufexor level, 
noting time elapsed since last dose.
Aliskiren, direct renin inhibitors Any use from first 
drug intake to end -
of-study visitDiscontinue direct renin inhibitor, if 
possible. If not possible, stop nidufexor 
and check a random nidufexor level, 
noting time elapsed since last dose.
ACEI + ARB in combination Any use from first 
drug intake to end -
of-study visitDiscontinue either ARB or ACE inhibitor, 
if possible. If not possible, stop 
nidufexor and check a random nidufexor 
level, noting time elapsed since last 
dose
Sodium -glucose co -transporter 2 
(SGLT2) inhibitorsAny use from first 
drug intake to end -
of-study visitDiscontinue SGLT2 inhibitors, if 
possible. If not possible, stop nidufexor 
and check a random nidufexor level, 
noting time elapsed since last dose.
GLP-[ADDRESS_1020660] been met:
Usage is considered medically  necessary , and
Dose has been stable for at least 1 month prior to screening , and
Dose is expected to remain stable for the duration of the study
[COMPANY_001] Confidential Page 41
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
No new use of these medications is allowed after entering the study , with the exception of drugs 
to control medically  significant elevations in LDL -C,which has been confirmed upon repeat 
testing.
A stable dose of insulin is defined as being within 25% of the current dose. A stable dose of 
oral anti-diabetic medications is defined as up to one step-up or step- down from the dose at 
randomization, per local treatment guidelines. For all other medications listed in Table 6-3, the 
definition of stable will be left to investigator discretion.
Table [ADDRESS_1020661] 1 month prior to 
randomization
Medication
Oral anti -diabetic medications such as metformin, sulfonylureas (including glyburide
(glibenclamide), meglitinides (such as repaglinide) and thiazolidinediones (including pi[INVESTIGATOR_746194])1
Insulin (within 25% of the dose at randomization)2
Beta- blockers and th iazide diuretics. Thiazide diuretic use should also be maintained constant
throughout the trial, if possible.
Fibrates, statins1niacin, ezetimibe3
Vitamin E
Thyroid hormone
Psychotropic medications (phenothiazines or second generation antips ychotics)
Horm onal (estrogen, progesterone, or estrogen/progesterone containing) birth control
1There is a potential for nidufexor to increase exposure of drugs metabolized by [CONTACT_097]2C8 (including 
repaglinide, pi[INVESTIGATOR_110248]) and those dependent on export by [CONTACT_69811] (potentially 
glyburide (glibenclamide), atorvastatin, rosuvastatin and pi[INVESTIGATOR_2830]). Careful attention MUST be paid 
to the drug interaction sections of the prescribing information for these compounds 
2Unless adjustment is required due to intercur rent illness; 
3Unless adjustment is required to treat medically significant increases in LDL -C that have been 
confirmed upon repeat testing.
6.2.3 Restriction for study  patient s
For the duration of the study , the patients should be informed and reminded of the restrictions 
outlined in this section. See also male and female contraception requirements in Section 5.2
In the event apatient presents with symptoms of COVID -19, the Investigator should ask the 
patient to quarantine per local guidelines.
[IP_ADDRESS] Dietary  restrictions and smoking
No special restrictions for the study . Appropriate diet for ty pe 2 diabetes should be followed.
[IP_ADDRESS] Other restrictions
None.
[COMPANY_001] Confidential Page 42
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
6.3 Patient numbering, treatment assignment, randomization
6.3.1 Patient numbering
The patient number assigned to a patient at screening remains the unique identifier for the 
patient throughout the study . For information on patient numbering, please see ‘patient 
numbering’ section in the Site Operations Manual.
6.3.[ADDRESS_1020662] of a 
randomization number. Randomization numbers will be assigned in ascending, sequential order 
to eligible patients (see Site Operations Manual for details). However, ra ndomization numbers 
will not be shared with the study staff, and will remain on the back- end of the I RT s ystem. 
The randomization number is only used to identify  which treatment the patient has been 
randomized to receive. The patient number assigned to a patient at screening remains the unique 
identifier for the patient throughout the stud y.
The randomization numbers will be generated using the following procedure to ensure that the 
treatment assignment is unbiased and concealed from p atients and investiga tor staff:
A patient randomization list will be produced by  [CONTACT_941] I RT provider using a validated
system that automates the random assignment of treatment arms to randomization
numbers.
Note: 
These randomization numbers are linked to the different treatment arms.
The randomization scheme for patients will be reviewed and approved b y a member of the
Randomization Office. If a patient is deemed eligible for enrollment into the study, they
will be randomized and treatment will be assigned via the I RT s ystem.
Patients will be assigned randomization numbers 5101-5340.
Note: Follow the details outlined in the Site Operations Manual regarding the
process and timing of treatment assignment and randomization of patients.
6.4 Treatment blinding
This is a patient -and investigator -blinded study . Patients, investigators, and sponsor staff 
(seeTable 6-4) will remain blinded to study  treatment throughout the study , except where 
indicated below.
The identity  of the treatm ents will be concealed by [CONTACT_50090], labeling, schedule of administration, appearance, and odor.
6.4.1 Treatment blinding -study staff
All study  staff (including st udy investigator, study  nurses/coordinators ) will be blinded to study  
treatment throughout the study .Unblinding a single patient for safet y reasons (i.e.necessary  for 
patient safet ymanagement) will occur via an emergency s ystem (see SOM and IRT manual for 
details)
.
[COMPANY_001] Confidential Page 43
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
6.4.2 Treatment blinding - sponsor staff
The following are unblinded sponsor roles :
Sponsor randomization office
Drug supply  (global clinical supplies)
Study statistician
The study  statistician will be able to access the randomi zation list and is allowed to
share unblinded information with the rest of the clinical team as appropriate for
internal decision purposes .For example, unblinded summaries and unblinded
individual data can be shared with the team for interim analyses.
The following are additional unblinded sponsor roles :
Medical lead (study  safety  physician / TME) and sponsor pharmacovigilance staff
Note: The TME and pharmacovigilance staff may have access to individual,
group/cohort, or the entire study treatment allocations as needed to oversee safety on
the trial.
Other sponsor roles:
The sample analy sts will receive a copy  of the randomization schedule (via request to
the Randomization Office), to facilitate anal ysis of the PK samples. The sample
analysts will provide the samp le data to the stud y team under blinded conditions
unless otherwise allowed.
Study  programmers and other personnel involved in study  data anal ysis (e.g. PK
expert, ) are allowed to access treatment assignment information for 
the purpose of conducting interim analy sesof the data .
The clinical trial team is allowed to share unblinded results with other sponsor staff
(e.g. decision boards) as required for internal decision making on the stud y or the
project at the time of interim analy ses whil e the study  is ongoing.
All unblinded personnel will otherwise keep randomization lists and data or
information that could unblind other study  team members confidential and secure
except as described above.
CCI
[COMPANY_001] Confidential Page 44
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Following final database lock ALL roles are cons idered unblinded.
Table 6-[ADDRESS_1020663] generatedTreatment 
allocation & 
dosingSafety  event 
(single subject 
unblinded)Interim 
Anal ysis 
Patient B B UI* B
Site staff, including PI , SC, study nurses
and mobile health professionalsB B UI* B
Unblinded Pharmacovigilance sponsor 
staffB UI UI UI
All other sponsor staff, including:
TME
Study Leader
Bio-analysts, including PK and
BMD
Bio-experts, including PK and
BMD
Statistical programmers
Data analysts
Clinical trial team members
Sponsor management and
decision boards
Supportive functionsB UI UI UI
Drug Supply (Global Clinical Supplies) UI UI UI UI
Sponsor Randomization Office UI UI UI UI
Study Statistician UI UI UI UI
Key:
*Unblinding allowed at the single patient level ONLY
UI: Allowed to be unblinded on individual patient level (includes single patient, group/cohort 
of patients, or entire study/all patients)
B: Remains blinded
6.5 Dose escalation and dose modification
Investigational or other study  treatment dose adjustments and/or interruptions should be kept as 
short as possible and dates recorded in the eCRF. Ifthese arefor reasons of significant 
noncompliance or extended dosing interruptions related to AEs, the investigator should use 
discretion to discontinue the patient from study  treatment. The investigator may consult with 
the Sponsor medical lead if necessary . 
Commercially Confidential Information
[COMPANY_001] Confidential Page 45
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
If this modification is not tolerated, the medication should be discontinued. Please refer to
Section 9.1.1.
If the reduced dose is tolerated, an attempt to increase the dose after two weeks ofreduced 
dosing could be considered or the reduced dose can continue for the remainder of the study .
Use of bile acid binding resins for treatment of pruritus is not recommended.
The ability  to reduce the dose is clinicall y relevant as data generated after dose reduction will 
provide further information regarding the tolerability  and safet y of nidufexor .
In the event a patient develops flu-like symptoms during the treatment period and the 
investigator is concerned the patient may have a COVID -[ADDRESS_1020664] to confirm the infection
within approximately  5 day s.
If the test is positive, the investigator may  decide to extend the treatment interruption and 
monitor the patient’s condition to determine if discontinuation is warranted. Treatment 
interruption should not exceed 14 day s.
If the test is negative, the inves tigator may decide to resume study  treatment.
6.[ADDRESS_1020665] promote compliance by [CONTACT_746209], and by [CONTACT_746210]’s safet y and 
the validity  of the study. The patient must also be instructed to contact [CONTACT_087]/she 
is unable for an y reason to take the study  treatment as prescribed .
Compliance will be assessed by [CONTACT_11219]/or study  personnel (or delegate) at each 
visit using pi[INVESTIGATOR_746195]. This information should be 
captured in the source document at each visit. All study treatment dispensed and returned must 
be recorded in the Drug Accoun tability  Log. Patients who are not >80% compliant with study  
drug administration will be counseled by [CONTACT_746211]. Dose reductions due to tolerability  issues 
shoul d not be factored into the compliance calculation. 
6.6.[ADDRESS_1020666] be recorde d on the Concomitant Medications/Significant 
non-drug therapi[INVESTIGATOR_50061].
[COMPANY_001] Confidential Page 46
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
6.6.[ADDRESS_1020667] the participant’s next 
treatment regimen, and after discussion and agreement with the sponsor. Most often, study 
treatment discontinuation and knowledge of the possible treatment assignments are sufficient 
to treat a stud y patient who presents with an emergency condition. 
Emergency  treatment code breaks are performed using the IRT. When the investigator contacts 
the system to break a treatment code for a patient, he/she must provide the requested patient 
identify ing information and confirm the necessit y to break the treatment code for the patient. 
The investigator will then receive details of the investigational drug treatment for the s pecified 
patient and a fax or email confirming this information. Thesystem will automatically  inform 
the [COMPANY_001] monitor for the site and the study  team that the code has been broken.
It is the investigator’s responsibility  to ensure that there is a depe ndable procedure in place to 
allow access to the IRT at any  time in case of emergency . 
The investigator will provide:
protocol number
protocol title
patient number
In addition, oral and written information to the patient must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at an y time.
Patients should be discontinued from the study  after emergency  unblinding but should not be 
considered withdrawn from the study . Where possible, they should return for end-of-study  
assessments as described in Section 9.1.1 .
6.7 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under the 
investi gational and control drugs section.
A unique medication number is printed on the study medication label.
Investigator staff will identify the stud y medication kits to dispense to the patient by [CONTACT_37246](s). 
Nidufexor will be administered to the patient via the oral route. On study  visit days, 
administration will occur in the presence of the study  nurse or delegate . At home, the patient 
will self -administer study medication. See the Site Operations Manual for fu rther details.
[COMPANY_001] Confidential Page 47
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
7 Informed consent procedures
If applicable, in cases where the patient's representative(s) gives consent (if allowed according 
to local requirements), the patient must be informed about the study  to the extent possible given 
his/her understanding. If the patient is capable of doing so, he/she must indicate agreement by 
[CONTACT_37249] y signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedure s described in the protocol). The process of obtaining informed consent must be 
documented in the patient source documents.
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form that complies with the ICH GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by [CONTACT_49413] I RB/IEC.
Information about common side effects alrea dy known about the investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the patient 
informed consent and should be discussed with the patient during the study  as needed. Any new 
information regarding the safet y profile of the investigational drug that is identified between IB 
updates will be communicated as appropriate, for example, via an investigator notification or 
an aggregate safet y finding. New information might require an update to the informed c onsent 
and then must be discussed with the patient.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirements.
Male patients must be informed that if a female partner becomes pregnant while he is enrolled 
in the study , contact [CONTACT_746212].
Refer to the Site Operations Manual for a complete list of I CFs included in this study .
Commercially Confidential Information
[COMPANY_001] Confidential Page 48
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
8 Visit schedule and assessments
The assessment schedule lists all of the assessments and indicates with an “X”, the visits when they are performed. All data obtained from 
these assessments must be suppor ted in the patient’s source documentation. Some assessments in the schedule are marked with an "S" 
indicating that these data are to be evaluated and stored as source data at the site.
Patients should be seen for all visits/assessments as outlined in the assessment schedule or as close to the designated day/time as possible. 
Missed or rescheduled visits should not lead to automatic discontinuation. This also applies in the event a patient needs to be quarantined for 
an amount of time consistent with local p olicy  due to exposure to or suspected or confirmed COVID -19 infection.  
For patients who withdraw from the study  (i.e. withdrawal of consent), no further assessments will be conducted. Further atte mpts to contact 
[CONTACT_746213], unless safet yfindings require communicating or follow up.
All study  assessments described in Table 8-1may potentially  be performed remotel y. Implementation of decentralized trial models is 
dependent on local regulations and Sponsor approval. 
Table 8-1 Assessment Schedule
Visit Name /Epoch Screening Treatment EOSPost Study 
Safety 
Contact
[CONTACT_221981]11 101 102 10321042105210621072199
Days -30 to -1 114
±529
±557
±585
±5113
±5141
±5169
±5197
±5
Time (post-dose) - 0h21h 2h 4h 6h 0h21h 2h 4h 6h - - - - - - -
Informed consent X
Inclusion / exclusion criteria X
Medical history/current medical conditions X
Demography X
Body height X
Body weight X X X X X X X X X4
Commercially Confidential Information
[COMPANY_001] Confidential Page 49
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Visit Name /Epoch Screening Treatment EOSPost Study 
Safety 
Contact
[CONTACT_221981]11 101 102 10321042105210621072199
Days -30 to -1 114
±529
±557
±585
±5113
±5141
±5169
±5197
±5
Time (post-dose) - 0h21h 2h 4h 6h 0h21h 2h 4h 6h - - - - - - -
Waist and hip circumferences5X X X X X X X X X
Body temperature X X X X X X X X X4
Blood pressure X X X X X X X X X4
Pulse rate X X X X X X X X X4
Physical examination S S S S S S S S S4
Electrocardiogram (ECG)6X X X X X X X X X4
Hepatitis screen S
COVID -19 (SARS- Cov2) testing21S
Alcohol test and drug screen S
Pregnancy and assessments of fertility7X X4
Clinical Chemistry X X X X X X X X X4
Hematology X X X X X X X X X4
PT/INR8X
Anticoagulant Panel 
(PT/INR; aPTT; fibrinogen)X X X
Plasma osmolality X X4
HbA1c X X X4
Fasting lipid panel X X X
Lipoprotein (a) [Lp(a)] X X X
PK blood collection10X2X X X X X2X X X X X2X2,4
Urinalysis12X X X X X X X X X4
Urine albumin and creatinine13X X X X X X X X X4
Commercially Confidential Information
[COMPANY_001] Confidential Page 50
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Visit Name /Epoch Screening Treatment EOSPost Study 
Safety 
Contact
[CONTACT_221981]11 101 102 10321042105210621072199
Days -30 to -1 114
±529
±557
±585
±5113
±5141
±5169
±5197
±5
Time (post-dose) - 0h21h 2h 4h 6h 0h21h 2h 4h 6h - - - - - - -
Urine protein13X X X X X X X X4
24-hr urine collection16X X4
Visual analog scale (VAS) -Itch17X X X X X X X X
Randomization X
Study drug administration18X X X X X X X
Collect study drug/drug accountability19X X X X X X X4
Dispense study medication X X X X X X X
Concomitant medications20X X X X X X X X X4
Serious adverse events As required4
Comments As required
Study completion information X4
Safety follow up call X
Commercially Confidential Information
[COMPANY_001] Confidential Page 51
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
XAssessment to be recorded in the clinical database
SAssessment to be recorded in the source documentation only
1Visit structure given for internal programming purpose only
2Assessments must be performed pre-dose
[ADDRESS_1020668] and hip circumferences (measured in cm); see the SOM for detailed explanation
6ECG as triplicat e measures
7A serum pregnancy test will be performed a t screening; a urine pregnancy test will be used at end of study .
8Prothrombin Time/International Normalized Ratio
9Intentionally deleted in Protocol Amendment V03
10PK samples will be collected af ter patients have been fasting for at least 6 hours
11
12Dipstick measurements /macroanalysis for specific gravity,  protein, glucose and blood will be performed. 
Microscopy, WBC, RBC and sediments will also be assessed in case of an abnormal dipstick test.
13Urine creatinine is collected in parallel with urine albumin and urine protein for the calculation of urine albumin -
to-creatinine ratio (UACR). Note: The sample should be obtained from the 24 -hour urine sample at time points 
when 24 -hour collection is required.  For visits that are not preceded by a 24-hour collection or due to a 
premature discontinuation , a separate spot urine sample will be collected and processed during the visit. A 
second morning void is preferred . If sample quantify is sufficient, then the same 2nd morning void may be used 
for other urine related assessments.
14Intentionally deleted in Protocol Amendment V03
15At time points when 24-hour collec tion is done prior to a visit , a separate spot urine sample will be collected  
and processed promptly. A second (2nd) morning void is preferred . If sample quantify is sufficient, then the same 
2ndmorning void may be used for other urine related assessment s. 
1624-hour urine collection should be performed as an outpatient, with in 1-2 days prior to the study v isit, and 
brought to the study vi sit, using supplied collection kit + instructions , as applicable . Quantify theurine volume 
and measure sodium, creatinine, protein, osmolality, and albumin (assays).
17PRO: VAS assessment for itching of the skin
18On study visit days, study drug should not be taken until after s tudy visit assessments are completed
19Collect unused study drug, perform drug accountability (pi[INVESTIGATOR_692]) and document compliance with protocol 
instructions
20A thorough review of any concomitant medications (including medication name, dose, unit, frequency, and 
route) should be performed at every visit.
21It is highly recommended that PCR testing for COVID -[ADDRESS_1020669] dosing.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 52
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
8.1 Screening
In general ,it is permissible to re -screen a patient if he/she fails the initial screening, if deemed 
feasible or necessary  by [CONTACT_746214]. If a subsequent re-screen is required after 
the first permissible re-screening (i.e. an additional re-screening attempt), the case should be 
discussed with the Sponsor. Additional re-screenings may be approved on a case-by-case basis. 
Further information on re -screening is outlined in the Site Operations Manual.
8.1.1 Information to be collected on screening failures
Patients who sign an informed consent but fail to be started on treatment for any reason are 
considered a screen failure. Information on data collected for screening failures is available in 
the SOM.
8.2 Patient demographics/other baseline characteristics
Patient demographic and baseline characteristic data will be collected on all enrolled patients. 
Details on additional data collected are outlined in the Site Operations Manual.
Investigators have the discretion to record abnormal test findings on the medical history  CRF, 
if in their judgment, the test abnormality  occurred prior to the informed consent signature.
8.2.[ADDRESS_1020670], Drug screen
All patie nts will be screened for alcohol and substances of abuse. See the Site Operations 
Manual for details.
8.3 Efficacy  and Pharmacody namics
Efficacy  and Pharmacody namics (PD) of nidufexor will be assessed based on measures 
including renal function and ty pe 2 diabe tes status.
Pharmacod ynamic samples will be collected at the time points defined in the 
Assessment Schedule . Follow the instructions outlined in the Site Operations Manual regarding 
sample collection, numbering, processing and shipment. In order to better define the PD profile, 
the timing of the sample collection may be altered based on emergent data. Results will remain 
blinded to the patient, investigative personnel, and blinded sponsor personnel regarding the 
associate dtreatment assignment throughout the study , as applicable . The number of 
samples/blood draws and total blood volume collected will not exceed those stated in the 
protocol. The PD samples will be obtained and evaluated in all patients.
8.3.1 Renal function assessments, markers of diabetic nephropathy
The following assessment will profile renal function, which are markers of diabetic 
nephropath y:
Urine albumin -creatinine ratio (UACR) at serial time points, as specified in the
Assessment Sched ule
[COMPANY_001] Confidential Page 53
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
24-hour urinary  collection at baseline and end of study , measured for albumin
Estimated glomerular filtration rate (eGFR), as determined b y the Chronic Kidney Disease
Epi[INVESTIGATOR_8849] (CKD -EPI) equation. ( Leve yand Stevens 2010 )
Free water clearance
8.3.2 Type 2 diabetes measures
The following assessments will be used to measure Ty pe 2 diabetes status:
HbA1c
Weight, BMI, waist -to-hip ratio
Fasting lipid profile to include total cholesterol, HDL  cholesterol, LDL cholesterol,
triglycerides and Lp(a)
8.3.3 Appropriateness of efficacy  assessments
Change in albuminuria (UACR and 24-hour urine albumin excretion) and annualized rate of 
change in eGFR over the 24-week treatment period are the primary  and secondary  endpoints, 
respectivel y. These two parameters comprise the current gold standard (Levey et
al2015) for 
assessing stage and progression of proteinuric chronic kidney  diseases such as diabetic 
nephropath y secondary to Type [ADDRESS_1020671] diagnostic 
measures in clinical practice. (UACR sensitivity = .85 and specificity  =.88; eGFR sensitivit y 
=.91 and specificit y =.87). The efficacy  measures for type 2 diabetes are recognized by [CONTACT_561478], diabetes organizations, and payers as the essential surrogate and diagnostic 
measures used for patient monitoring to help patients manage the disease, reduce diabetes 
symptoms and, if well controlled, minimize or ameliorate diabetes related end organ damage.
8.4 Safet y and Tolerability
Safety  assessments are specified within the section below. The methods for recording the 
assessments are specified in the Site Operations Manu al. The Assessment Schedule 
(Table 8-1)details the timing of when each assessment is to be performed.
For details on AE collection and reporting, refer to AE section
 (Section 10.1.1 ).
8.4.[ADDRESS_1020672] be recorded as an adverse 
event. See the SOM for details.
8.4.2 Vital signs
Vital signs include BP and pulse measurements. See the SOM for details.
[COMPANY_001] Confidential Page 54
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
8.4.[ADDRESS_1020673] be r ecorded on the relevant section of the medical 
history /Current medical conditions/AE CRF/ e(CRF) page as appropr iate. Clinically  relevant 
deviations of laboratory  test results occurring during or at completion of the study  must be 
reported and discussed with [COMPANY_001] personnel. The results should be evaluated for criteria 
defining an adverse event and reported as su ch if the criteria are met. Repeated evaluations are 
mandatory  until normalization of the result(s) or until the change is no longer clinicall y relevant. 
In case of doubt, [COMPANY_001] personnel should again be contact[INVESTIGATOR_530].
[IP_ADDRESS] Hematology
Hemoglobin, hematocrit, redblood cell count, white blood cell count with differential and 
platelet count will be measured. A coagulation panel including PT/INR, aPTT, and fibrinogen 
will be measured.
[IP_ADDRESS] Clinical chemistry
Sodium, potassium, creatinine, BUN/urea, uric acid, chloride, albumin, calcium, phosphate, 
bicarbonate/HCO 3, LDH, amy lase, lipase, creatine kinase (CK), glucose
[IP_ADDRESS] Liver function tests
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBL), 
serum albumin (Alb), prothrombin time (PT)/ international normalized ratio (INR), alkaline 
phosphatase (ALP), gamma -glutam yl transferase (γGT)
[IP_ADDRESS] Urinaly sis and renal function
Dipstick /macroanaly sismeasurements for specific gravity , protein, glucose and blood will be 
performed. Microscopy , WBC, RBC and sediments will also be assessed in case of an abnormal 
dipstick test.
The following assessments for renal function will also be completed:
Urine albumin -creatinine ratio (UACR) at serial time points, as specified in the 
Assessment Schedule
24-hour urinary  collection at baseline and end of study , measured for albumin
Estimated glomerular filtration rate (eGFR), as determined by [CONTACT_488060][INVESTIGATOR_8849] (CKD -EPI) equation ( Leve yandStevens 2010 ).
Free water clearance
[COMPANY_001] Confidential Page 55
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
[IP_ADDRESS] Type 2 diabetes and gly cemic control
HbA1c
Fasting lipid profile (total cholesterol, HDL -C, LDL -C, trigl ycerides and Lp(a))
8.4.4 Electrocardiogram (ECG)
Triplicate twelve -lead ECGs will be collected at the time-points specified in the 
Schedule ofAssessments . At each time point, three serial 12 -lead ECGs, at 5 minute inter vals, 
will be recorded. Full details of all procedures relating to the triplicate ECG collection and 
reporting are contained in the ECG technical manual and SOM .
PR interval, QRS duration, heart rat e, RR, QT, QTc will be assessed
The Fridericia QT correction formula (QTcF) (calculated with the RR interval expressed 
in seconds) should be used for clinical decisions
If clinicall y significant abnormalities are identified that were present prior to the informed 
consent signature, then it should be recorded on t he relevant medical history  CRF page.
After informed consent signature, an y clinically significant abnormalities are recorded on 
the Adverse Events page thereafter. 
Clinically  significant findings MUST be recorded on the AE CRF and should be 
discussed wit h the sponsor in a timely  fashion.
8.4.[ADDRESS_1020674]- treatment follow up period (see Section 10.1.4 ).
If additional pregnancy testing is needed per local requirements, those additional results will be 
kept as source documentation only .
8.4.6 Appropriateness of safety  measurements
Planned safet y assessments are based upon expected organ toxicity  as discussed in the rationale 
of study  design ( Section 4.1) and risk- benefit secti ons ( Section 4.5).
8.5 Additional assessments
8.5.1 Clinical Outcome A ssessment -Visual A nalog Scale (VA S)
The participant must be given the PRO measure(s) to be completed at the scheduled visit before 
any clinical assessments are conducted. Participant’s refusal to complete all or any part of a 
PRO measure should be documented in the study  data capture system and should not be 
captured as a protocol deviation. Handling of protocol deviations can be modified if needed.
Participant q uestionnaires should be completed in the language most familiar to the participant.
[COMPANY_001] Confidential Page 56
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
The participant should be given sufficient space and time to complete the PRO measure(s).
The site personnel or delegate should check PRO measure(s) for completeness and ask the 
participant to complete any missing responses. The responses stored electronicall y in the 
database will be considered the source file.
Completed measure(s) (including when using paper PRO measures and any unsolicited 
comments written by [CONTACT_47992]) must be reviewed and assessed by [CONTACT_746215] . This assessment should be documented in study  source records. If AE or SAE 
are confirmed, thestudy  investigator should not encourage the participant to change responses 
reported in the completed questionnaires. Study  investigators must follow reporting instructions 
outlined in Section 10.1.1 of the study  protocol .
A 10 cm visual analogue scale (VAS) will be used to assess the severity  of patients itch (ranging 
from 0 = no itch at all, to 10 = the worst itch imaginable itch). The score (distance from left) on 
the VAS will be recorded by [CONTACT_102] b y marking with a line and used to test for an effect of 
nidufexor over placebo. The scale will be completed by [CONTACT_746216] 8-1
(Assessment schedule).
8.5.2
Pharmacokinetics
PK samples will be collected at the time points defined in the Assessment schedule, Table 8-1. 
Follow instructions outlined in the central laboratory  manual and SOM regarding sample 
collection, numbering, processing and shipment. See Section [IP_ADDRESS] regarding the potential use 
of residual samples.
Commercially Confidential Information
[COMPANY_001] Confidential Page 57
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 58
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
[ADDRESS_1020675] discontinue study  treatment for a given patient if he/she believes that 
continuation would negatively  impact the patient's well -being.
Study treatment MUST be discontinued under the following circumstances:
Hypersensitivity  (CTCAE grade 2 or higher, CTCAE Version 5.0) reaction to nidufexor .
Adverse events, abnormal laboratory  values or abnormal test result that indicate a safet y
risk to the patient, in the opi[INVESTIGATOR_871]
An adverse event that is a CTCAE Grade 3 CTCAE Version 5.0 and believed to be related
to the study  drug (apart from liver and renal events - see below).
A liver safet y event with AL T, AST, total biliru bin and/or alkaline phosphatase elevations
mandating stud y treatment d iscontinuation. Please refer to Section 10.2.1 (Liver safety
monitoring), 
Table 16 -1andTable16-2 for further instructions and monitoring.
Commercially Confidential Information
[COMPANY_001] Confidential Page 59
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
A renal safet y event with serum creatinine elevations mandating stud y treatment 
discontinuation. Please refer to Section 16.3 andTable 16-3for further instructions and 
monitoring.
Pregnancy  (see Section 10.1.4 )
Any protocol deviation that results in a significant risk to the patient’s safety , in the 
opi[INVESTIGATOR_871].
Following emergency  unblinding
If apatient presents with COVID -[ADDRESS_1020676] determine the primary  reason 
for the patient’s premature discontinuation of study  treatment and record this information on 
the applicable CRF.
Patients who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent (Section 9.1.2 ). Where possible, they should be scheduled for a visit as soon as 
possible, at w hich time all of the assessments listed for the final visit should be performed , with 
top priority  for assessments as noted in t he Assessment Schedule for the EOS visit. At this final 
visit, all dispensed in vestigational product must be collected, andreconciled.
If they  fail to complete these assessments for unknown reasons, every  effort (e.g. telephone, e -
mail, letter) should be made to contact [CONTACT_180186]/pre -designated contact [CONTACT_746217] 9.1.3 (Lost to follow -up). This contact [CONTACT_746218] y should be done according to the 
study  visit schedule.
After study treatment discontinuation, the following data (at a minimum) should be collected at 
abbreviated study visits or via tel ephone/email contact:
new / concomitant treatments
adverse events/Serious Adverse Events
The investigator must also contact [CONTACT_105253]’s discontinuation from study  
treatment.
If discontinuation occurs because treatment code has been broken, please refer to emergency 
breaking of treatment code, Section 6.6.[ADDRESS_1020677] study  safety follow -up phone call approximately 
28 days after the patient’s last visit. In the event of withdrawal of consent, the study  staff should 
follow the guidance i n Section 9.1.2. The information collected is kept as source documentation. 
All SAEs reported during this time must be reported as described in Section 10.1.3 .
[IP_ADDRESS] Replacement poli cy
Patients will not be replaced.
[COMPANY_001] Confidential Page 60
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
9.1.2 Withdrawal of informed consent
Patients may voluntaril y withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs ONLY when a patient satisfies the following :
Does not want to participate in the study  anymore
AND
Does not allow further collection of personal data
Note : In this situation, the investigator should make a reasonable effort (e.g.
telephone, e -mail, letter) to understand the primary  reason for the patient’s decision to
withdraw his/her consent and record this information.
If withdrawal of consent occurs, then the study treatment must be discontinued, no further 
assessments conducted, and the data that would have been collected at subsequent visits will be 
considered missing. Further attempts to contact [CONTACT_746219] y 
findings require communicating or follow-up.
All efforts should be made to complete the allowable, necessary  assessments prior to study  
withdrawal , if possible . A final evaluation at the time of the patient’s study  withdrawal should 
be made as detailed in the Assessment table .
[COMPANY_001] will continue to keep and use collected study information (including any data resulting from 
the analy sis of a patien t’s samples until their time of withdrawal) according to applicable law.
For US: All biological samples not yet analy zed at the time of withdrawal may still be used for further 
testing/analy sis in accordance with the terms of this protocol and of the infor med consent form.
For EU and the Rest of World :All biological samples not yet analy zed at the time of withdrawal 
will no longer be used, unless permitted by [CONTACT_1289]. They  will be stored according to 
applicable legal requirements.
9.1.[ADDRESS_1020678] show "due diligence" by 
[CONTACT_268295] (e.g. dates of telephone 
calls, registered letters, etc.). A patient should not be considered as lost to follow - up until due 
diligence has been completed or until the end of the study .
9.1.4 Study stoppi[INVESTIGATOR_746196] y review undertaken if any of the 
following occurs cumulatively  across all of the cohorts:
Two or more stud y treatment -related SAEs
Two or more patients experience study  treatment -related h ypersensitivity  reactions of
CTCAE (Version 5) Grade 3 or higher in intensity ;
Three or more patients experience a similar AE as assessed by  [CONTACT_746220] (Version 5) Grade 3 or higher in intensity, and study  treatment -related;
The Sponsor considers that the number and/or severity  of AEs , abnormal safet y
monitoring tests or abnormal laboratory  findings justify  putting the stud y on hold.
[COMPANY_001] Confidential Page 61
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
The study  may resume following the safet y review, if the Sponsor judges it safe to proceed. 
Thestudy  will be stopped, and no further dosing will be taken pending a full safet y review, 
ifthe investigator and the Sponsor agree that it is unsafe to continue dosing.
9.1.5 Early  study termination by  [CONTACT_746221]. This may include reasons related 
to the benef it/risk assessment of participating in the study, practical reasons (including slow 
enrollment), or for regulatory or medical reasons. In making the decision to terminate, [COMPANY_001] 
will alway s consider patient welfare and safety . Should early termination be necessary , patients 
must be seen as soon as possible (provide instruction for contact[CONTACT_5713], when the patient 
should stop taking drug, when the patient should come for a final EOS visit) and treated as a 
prematurel y withdrawn patient. The invest igator may be informed of additional procedures to 
be followed in order to ensure that adequate consideration is given to the protection of the 
patient’s interests. The investigator or sponsor depending on the local regulation will be 
responsible for infor ming I RBs/IECs of the earl y termination of the trial.
9.[ADDRESS_1020679] day of study treatment is Day 168, the day 
before the End of Stud y visit. Study  treatment should not be taken on Day 169 –End of Study .
Study  completion is defined as when the last patient completes their End of Study  visit, and any 
repeat assessments associated w ith this visit have been documented and followed -up 
appropriatel y by [CONTACT_737], or in the event of an early study termination decision, the date 
of that decision.
All randomized and/or treated patients should have a post-study  safety follow -up contact 
[CONTACT_746222] [ADDRESS_1020680] the patient 
should be recorded in the source documentation.
Continuing care should be provided by [CONTACT_1755]/or referring physician based on 
patient availability  for follow -up. This care may include follow -upand treatment of all 
documented medical conditions according to local or global standards of care. [COMPANY_001] will not 
provide nidufexor for continuing care beyond the last visit foranypatient.
[COMPANY_001] Confidential Page 62
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign, including abnormal laboratory  findings , symptom or disease) in a patient or 
clinical investigation patient after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managi ng the safet y of individual patient and 
identify ing adverse events.
[COMPANY_001] qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by [CONTACT_105] -directive qu estioning of the patient at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the patient during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Advers e events must be recorded in the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, a ccompanied by [CONTACT_6644] (as far as 
possible) (if the event is serious refer to Section 10.1. 2).
1. S everity grading
Common Toxicity  Criteri a (CTC) AE grade (version 5.0) will be used in this study .Grade refers 
to the severity of the AE. The CTC -AE displays Grades 1 through 5 with unique clinical 
descriptions of severity  for each AE based on this ge neral guideline: 
Grade 1: Mild
Asymptomatic or mild symptoms; clinical or diagnostic observations o nly; 
intervention not indicated
Grade 2: Moderate
Minimal, local or noninvasive intervention indicated; limiting ag e appropriate 
instrumental ADL *
Grade 3: Severe
Medically  significant but not immediately  life-threatening; hospi[INVESTIGATOR_8942]; disa bling; limiting self -care ADL**
Grade 4: Life -threatening 
Life-threatening consequences ; urgent intervention indicated
Grade 5: Death 
Death related to AE
[COMPANY_001] Confidential Page 63
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Note s: 
There may be cases where a CTCAE with a grade of 4 (life-threatening) may not necessarily be an 
SAE (e.g. certain laboratory abnormalities in the absence of meet ing other seriousness criteria). 
CTC- AE grade 5 (death) is not used on the AE case report form but is collected as a seriousness 
criteria and is also collected in other CRFs (e.g study completion, death/survival) in the clinical 
databas e.
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the 
telephone, managing money, etc.
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden
2.Its relationship to the study treatment
Yes or No
If the event is due to lack of efficacy  or progression of underl ying illness (i.e. 
progression of the stud y indication) the assessment of causalit y will usually  be ‘Not 
suspected’
The rationale for this guidance is that the s ymptoms of a lack of efficacy  or 
progression of underly ing illness are not caused by  [CONTACT_6645], they  happen in spi[INVESTIGATOR_746197]/or both lack of efficacy  and progression of underly ing 
disease can only  be evaluated meaningfull y by [CONTACT_49430], not on a 
singl epatient
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.
4. Whether it constitutes a SAE (seeSection 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5. Action taken regarding with stud y treatment.
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Dose not changed
Drug temporarily interrupted with continued follow up
Drug permanently withdrawn
6. Its outcome
not recovered/not resolved;
recovered/resolved;
recovering/resolving,
recovered/resolved with sequelae;
fatal;
unknown.
[COMPANY_001] Confidential Page 64
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the patient.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for atleast [ADDRESS_1020681] be followed until its resolution or until it i s judged to 
be permanent (e.g. continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspected relationship to 
the interventions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator's Brochure (IB).
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinica lly significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typi[INVESTIGATOR_286813] s with 
the underl ying disease. Alert ranges for laboratory and other test abnormalities are included in 
Appendix 1.
Follow the instructions found in the Site Operations Manual and eCRF completion guidelines 
for data capture methodology  regarding AE collection for patients .
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), s ymptom(s) or medical condition(s) which meets any  one of the following 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused dea th if it were more severe (please refer to the ICH
-E15D Guidelines 2003 ).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_32957], unless
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any
deterioration in condition of diabetic nephropath y.
[COMPANY_001] Confidential Page 65
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
treatment on an emergency  outpatie nt basis for an event not fulfilling an y of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically  significant, e.g. defined as an event that jeopardizes the patient or may  require 
medical or surgical intervention to prev ent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_18534]. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospi[INVESTIGATOR_37209].
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse event.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irr espective of whether a clinical event has occurred.
10.1.[ADDRESS_1020682] be reported to 
Novar tis/safet y immediately , without undue delay , and under no circumstances later than 
24hours of learning of its occurrence. Detailed instructions regarding the submission process 
and requirements are to be found in the investigator folder provided to each site.
IMPORTANT: To comply with regulations, all suspected, unexpected, serious adverse 
reactions (S[LOCATION_003]Rs) occurring in a clinical trial must be reported in an expedited 
timeframe (7 or 15 days) to competent authorities.
1.Screen Failures (e.g. A patient who is screened but is not treated or randomized): SAEs 
occurring after the patient has provided informed consent until the time the patient is 
deemed a Screen Failure must be reported to [COMPANY_001]
2.Randomized OR Treated patients: SAEs collected until post- study call (contact).
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_30755] [ADDRESS_1020683] be reported separatel y as a new event.
If the SAE is not previously  documented in the Investigator’s Brochure and is thought to be 
related to the study  treatment, a Chief Medical Officer & Patient Safety  (CMO & PS) 
[COMPANY_001] Confidential Page 66
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Department associate may urgentl y require further information from the investigator for health 
authority  reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_1020684] study  visit and/or following the last 
administration of study  treatment (in the event of early  discontinuation) should only be reported 
to [COMPANY_001] Safet y if the investigator suspects a causal relationship to study treatment.
10.1.[ADDRESS_1020685] be reported to [COMPANY_001] within 24 hours of learning of its 
occurrence. The pregnancy  should be followed up to determine outcome, including spontaneous 
or voluntary  termination, details of the birth, and the presence or absence of any  birth defects, 
congeni tal abnormalities, or maternal and/or newborn complications.
Pregnancy  should be recorded and reported by [CONTACT_746223] & Patient Safety (CMO&PS) . Pregnancy follow -up should be recorded on the same form 
and should include an assessment of the possible relationship to the investigational/stud y 
treatment of any pregnancy  outcome. Any SAE experienced during pregnancy  must be reported.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
The newborn will followed up for at least one year after birth/EDD .
10.1.5 Reporting of study treatment errors including misuse/abus e
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient or 
consumer (EMA definition).
Misuse refers to situations where the medici nal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 
AE/SAE and reported to Safety  only if associated with an AE/SAE. M isuse or abuse will be 
collected and reported in the safet y database irrespective of it being associated with an AE/SAE 
within 24 hours of I nvestigator’s awareness.
[COMPANY_001] Confidential Page 67
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error 
typeDocument in Dose 
Administration (DA R) eCRF 
(Yes/No)Document in A E 
eCRFComplete SA E 
form
Unintentional study 
treatment errorYes Only if 
associated with 
an AEOnly if associated 
with an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a 
SAE
For more information on AE and SAE definition and reporting requirements, please see the, 
respective sections.
10.2 Additional Safety  Monitoring
10.2.1 Liver safety monitoring
To ensure patient safet y and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
Please refer to Section 16.2 in Appendix 2for complete definitions of liver laboratory  triggers 
and liver events.
Once a participant has been exposed to study  treatment, every liver event defined in
Section 16.2 should b e followed up by [CONTACT_746224], as summarized 
below. Additional details on actions required in case of liver events are outlined i n Section 16.2
Repeat liver chemistry  tests (ALT, AST, TBL, Direct Bilirubin, PT/INR, ALP a nd γ-GT) t o 
confirm elevation.
These liver chemistry  repeats will be performed using the central laboratory. If results will 
not be promptly  available from the central laboratory , then the repeats can also be 
performed at a local laboratory  to monitor the safety  of the patient. If a liver event is 
subsequently  reported, any  local liver chemistry  tests previously  conducted that are 
associated with this event should have re sults recorded on the appropriate CRF 
If the initial elevation is confirmed, close observation of the patient will be initiated, 
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to the discontinuation of study  treatment 
information located in Section 9), if appropriate
Hospi[INVESTIGATOR_18539]
Causality  assessment of the liver event
Thorough follow -up of the liver event 
These invest igations can include based on investigator’s discretion: serology  tests, 
imaging and pathology  assessments, hepatologist’s consultancy  
Obtaining a more detailed history  of symptoms and prior or concurrent diseases. 
[COMPANY_001] Confidential Page 68
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Obtaining a history  of concomitant drug use (including nonprescription medications and
herbal and dietary supplement preparations), alcohol use, recreational drug use, and special
diets.
Exclusion of underly ing liver disease.
Obtaining a history  of exposure to environmental chemical agents.
Considering gastroenterology  or hepatology  consultations.
All follow -up information, and the procedures performed must be recorded as appropriate in 
the liver event CRF.
Refer to the Site Operations Manual for additional details.
10.2.2 Renal safety  monitoring
Once a participant has been exposed to study  treatment, the following two categories of 
abnormal renal laboratory  alert values should be assessed during the study period:
Serum creatinine increase ≥25% compared to baseline during normal hydration status. B aseline 
serum creatinine is determined as the mean of two serum creatinine measurements (e.g. at 
screening and pretreatment).
Albumin -creatinine ratio (UACR) increase ≥ 2X baseline
Abnormal renal event findings must be confirmed within 24-[ADDRESS_1020686] assessment.
Once a participant is exposed to study  treatment, renal laboratory  alerts or renal safet y events 
should be monitored and followed up by [CONTACT_746225] 16-3 .
Every  renal laboratory  trigger or renal event as defined in Table 16-3 should be followed up b y 
the investigator or designated personnel as summarized in Section
16.3.
10.2.3 Fat soluble vitamin de ficiency  
Although no histological or laboratory  findings of fat soluble vitamin (A, Dand E) deficiencies 
were observed in the chronic toxicology  studies, this has not been assessed in humans and is a 
theoretical risk due to sustained partial suppression of bile acid synthesis in response to 
nidufexor . 
 The following treatment emergent AEs and laboratory  findings should prompt 
consideration of the corresponding vitamin deficiency :
Worsening night vision, xerophthalmia and new ichthy osis : Vitam in A deficiency
Hypocalcemia and s ymptoms of secondary  hyperparathy roidism: Vitamin D deficiency
Vertical gaze palsy , ataxia and hy poreflexia: Vitamin E deficiency
A vitamin deficiency identified during an AE evaluation should bereported in the Adverse 
Events CRF andmanaged according to the local standard of care.  Deficiency  of one fat soluble 
vitamin should prompt an assessment of the other two indicated above.
[COMPANY_001] Confidential Page 69
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
11 Data Collection and Database management
11.1 Data collection
Designated investigator staff will enter the data required by [CONTACT_37290] (eCRF). The eCRFs have been built using fully validated secure web-
enabled software that conforms to [ADDRESS_1020687] been trained. Automatic validation 
programs check for data discrepancies by [CONTACT_746226], 
which allow modification and/or verification of the enter ed data b y the investigator staff.
The investigator is responsible for assuring that the data entered into the eCRF is complete, 
accurate, and that entry and updates are performed in a timely  manner.
After final database lock, the investigator will receive copi[INVESTIGATOR_286744].
Data not requiring a separate written record will be defined in the Site Operations Manual and 
Assessment schedule (Table 8-1) and can be recorded directl y on the CRFs. All other data 
captured for this study  will have an external originating source (either written or electronic) 
with the CRF not being considered as source.
All data should be recorded, handled and stored in a way that allows its accurate repor ting, 
interpretation and verification.
11.2 Database management and quality  control
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432] . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator study  staff are required to 
respond promptly  to queries and to make any  necessary  change s to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and a dverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Randomization codes and data about all study  treatment(s) dispensed to the patient will be 
tracked using an Interactive Response Technology  (IRT). The system will be supplied by a 
vendor, who will also manage the database. The data will be sentelectronically  to [COMPANY_001] (ora 
designated CRO) at specific timelines.
Each occurrence of a code break via IRT will be reported to theclinical team and monitor.
Thecode break functionality  will remain available until study  shut down or upon request of 
[COMPANY_001].
[COMPANY_001] Confidential Page 70
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
11.3 Site monitoring
Before study  initiation, at a site initiation visit, virtual training event, or at an investigator’s 
meeting, a [COMPANY_001] delegated CRO representative will review the protocol and data capture 
requirements (i.e. eCRFs) with the investigators and their staff. During the study , [COMPANY_001] 
employ s several methods of ensuring protocol and GCP compliance and the quality /integrity  of 
the sites’ data. The field monitor will check the completeness of patient records, the accuracy 
of data capture / data entry , the adherence to the protocol and to Good Clinical Practice, the 
progress of enrollment, and to ensure that study treatment is being stored, dispensed, and 
accounted for according to specifications. Key study personnel must be available to assist the 
field monitor during these visits. Continuous remote monitoring ofeach site’s data may be 
performed b y a centralized [COMPANY_001] delegated CRO/CRA organization. Additionally , a central 
analytics organization may analyze data to identify  risks and trends for site operational 
parameters, and provide reports to [COMPANY_001] clini cal teams to assist with trial oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient’s file. Data not requiring a separate written record will be defined before stud y start and 
will be recorded directl y on the CRFs. The investigator must also keep the original informed 
consent form signed b y the patient (a signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their
consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the CRFs are performed according to the 
study -specific monitoring plan. No information in source documents about the identity  of the 
patients will be disclosed.
12 Data analy sis a nd statistical methods
Any data analy sis carried out independently  by [CONTACT_85689].
Commercially Confidential Information
[COMPANY_001] Confidential Page 71
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
12.[ADDRESS_1020688] one available valid (i.e. not flagged 
for exclusion) PK concentration measurement, who received any study drug and with no 
protocol deviations that impact PK data.
The PD analy sis set will include all patients with available PD data and no protocol deviations 
with relevant impact on PD data.
Protocol deviation impact will be documented appropriatel y and  assessed by [CONTACT_746227] y 
team, including the Medical and Study  Leads with input from of the trial team. 
12.[ADDRESS_1020689], 
which employ s the Anatomical Therapeutic Chemical classification system. 
12.4 Analysis of the primary  endpoint(s)
The primary  objective of this study  is to assess the safet y and tolerability  of nidufexor as well 
as the efficacy  of nidufexor on albuminuria in patients with diabetic nephropath y during
24weeks of treatment.
12.4.1 Definition of primary  endpoint(s)
For anal ytical purposes, all safet y data, including laboratory  measurements, vital signs, adverse 
events, ECG, are considered primary  endpoints.
For efficacy  evaluation, log-transformed ratios to baseline UACR and 24-hour urine albumin 
excretion at Week 24 are the primary  endpoints.
12.4.2 Statistical model, hypothesis, and method of analy sis
[IP_ADDRESS] Safety  endpoints
For all safet y analyses, the safety  set will be used. Safety  and tolerability  data will be 
summarized. Formal statistical analysis will not be performed on the safety  and tolerability  data.
[COMPANY_001] Confidential Page 72
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Adverse events
All information obtained on AEs will be display ed by  [CONTACT_90217].
The number (and percentage) of patients with treatment emergent adverse events (events started 
after the first dose of study  medication or events present prior to start of treatment but increased 
in severity  based on preferred term) will be summarized in the following way s:
by [CONTACT_3148], primary  system organ class and preferred term.
by [CONTACT_3148] , primary  system organ class, preferred term and maximum CTCAE grade
Separate summaries will be provided for study  medication related AEs, death, SAEs, other 
significant AEs and AEs leading to discontinuation.
A patient with multiple AEs within a primary  system organ class is only  counted once towards 
the total of the primary  system organ class.
Vital signs
All vital signs data will be listed by [CONTACT_1570], patient, and visit/time and if ranges are 
available, abnormalities (and relevant orthostatic changes) will be flagged. Summary  statistics 
will be provided by  [CONTACT_10659]/time.
12-lead ECG
All ECG data will be listed by [CONTACT_1570], patient and visit/time, abnormalities will be 
flagged. Summary  statistics will be provided by  [CONTACT_10659]/time.
Clinical laboratory  evaluations
All laboratory  data will be listed by [CONTACT_1570], patient, and visit/time and abnormalities 
will be flagged. Summary  statistics will be provided by  [CONTACT_10659]/time.
[IP_ADDRESS] Efficacy  and/or Pharmacody namic Endpoints
For all efficacy  PD anal yses, the PD set will be used.
A repeated measures Analy sis of Covariance (ANCOVA) will be performed for log-
transformed ratio to baseline UACR measured at each visit. The model will include effects for 
log-transformed baseline, treatment, visit, treatment by [CONTACT_746228]-transformed baseline interaction. An unstructured variance -covariance matrix will be used 
to account for correlation among multiple measurements from the same patient and variance 
heterogeneity .
Similarly  an ANCOVA with treatment as the classification factor and log- transformed baseline 
as the covariate will be conducted for log -transformed ratio to baseline [ADDRESS_1020690] 25% in favor of nidufexor 
will be considered clinically  significant.
[COMPANY_001] Confidential Page 73
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
12.4.3 Handling of missing values/censoring/discontinuations
Missing data will not be imputed.
Assuming missing at random, a patient with missing value at a visit will still contribute to the 
estimation of the treatment effect at that particular visit as the likelihood -based repeated 
measures ANCOVA borrows information from non-missing values of this patient and other 
patients.
12.4.4 Sensitivity and Supporti ve analy ses
12.5 Analysis of secondary  endpoints
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s)
Log
-transformed ratio to baseline for eGFR, free water clearance, HbA1c and fasting lipid 
profiles (total cholesterol, HDL, LDL, triglycerides and Lp(a)) as well as change from baseline 
in weight, BMI and WTH ratio will be analy zed using the same repeated measures ANCOVA 
described in Section 12.4.[ADDRESS_1020691]-treatment measurement an 
ANCOVA with treatment as a classification factor and baseline (or log -transformed baseline if 
applicable) as a covariate will be employ ed.
12.5.2 Pharmacokinetics
Nidufexor plasma concentration data will be listed by [CONTACT_69867]/sampling time point. 
Descriptive summary  statistics will be provided by [CONTACT_765]/sampling time point, including the 
frequency  (n, %) of concentrations below the LLOQ and reported as zero.
Summary  statistics will include mean (arithmetic and geometric), SD, CV (arithmetic and 
geometric), median, minimum and maximum. An exception to this is Tmax where median, 
minimum and maximum will be presented. Concentrations below LLOQ will be treated as zero 
in summary  statistics and for PK parameter calculations. A geometric mean will not be reported 
if the dataset includes zero values. Pharmacokinetic parameters will be calculated as described 
in Section
8.5.[ADDRESS_1020692] provided at the 
beginning of this protocol.
The following pharmacokinetic parameters will be determined using the actual recorded 
sampling times and non-compartmental method(s) with Phoenix WinNonlin (Version 6.2 or 
higher): Cmax, Tmax, and AUClast from the plasma concentration -time data. The linear 
trapezoidal rule will be used for AUC calcul ation.
Commercially Confidential Information
[COMPANY_001] Confidential Page 74
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
12.5.5 PK/PD relationships
The relationship between key efficacy /PD parameters (includi ng, but not limited to UACR, 
24-hour urine albumin excretion and eGFR and nidufexor PK parameters (Cmax an d AUC0 -6)
may be explored using a graphical approach and descriptive statistics may be provided.
Additional 
statistical analy sis such as regression may be performed, if necessary . Modeling
approach may  also be used to explore the PK/PD interactions.
12.5.6 Patien t reported outcomes
Change from baseline itch VAS measurements will be analy zed using the same repeated 
measures ANCOVA described in Section 12.4.2.
Commercially Conf idential Information
Commercially Con
fidential Information
[COMPANY_001] Confidential Page 75
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
12.7 Interim analy ses
12.8 Sample size calculation
12.8.1 Primary  endpoint(s)
Data from 50 patients per arm will provide 72% power to detect the combination of a drug 
effect on UACR at Week 24 that is both clinically  significant (defined as an estimated relative 
reduc tion of at least 25% compared to placebo) and statistically  significant (defined as≥90% 
probability  of a > 0% reduction relative to placebo) if the true placebo adjusted reduction is 
30%. The figure below shows the probability  of decision making for vario us true drug effects 
at a sample size of 50 patients per arm. A “Go” decision will be made if both the clinical 
significance and the statistical significance criteria are met while a “No Go” decision will be 
made if neither the clinical significance nor the statistical significance criterion is met. 
Otherwise it will be an indeterminate situation requiring further information to be obtained 
before a decis ion can be made.
The power calculations were performed using simulations based on log-transformed ratio to 
baseline analysis. The standard deviation was assumed to be 0.6, estimated from published 
studies in the literature (Hanes et al 2018 ). Treatment comparison was based on a one-sided two 
sample t -test.
Commercially Confidential Information
[COMPANY_001] Confidential Page 76
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethic al 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics C ommittee (IRB/IEC) for the trial protocol, 
written informed consent form, consent form updates, patien t recruitment procedures 
(e.g., advertisements) and any other written information to be provided to patients. Prior to 
study  start, the investigator is required to sign a protocol signature [CONTACT_5389]/her 
agreement to conduct the study  in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records to 
[COMPANY_001] monitors, auditors, [COMPANY_001] Qualit y Assurance representatives, designated agents of 
[COMPANY_001], I RBs/IECs, and regulatory  authorities as required. 
Commercially Confidential Information
[COMPANY_001] Confidential Page 77
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
If an inspection of the clinical site is requested by a regulatory authority, the investigator 
must inform [COMPANY_001] immediately that this request has been made.
13.[ADDRESS_1020693] and/or as required by [CONTACT_746229] . In addition, after study 
completion (defined as last patient last visit) and finalization of the study  report the results of 
this trial will be submitted for publication and posted in a publicly  accessible d atabase of clinical 
trial results, such as the [COMPANY_001] clinical trial results website and all required Health Authority 
websites (e.g. Cl inicaltrials.gov, EudraCT etc.).
For details on the [COMPANY_001] publication policy  including authorship criteria, please refer to the 
[COMPANY_001] publication policy training materials that were provided to you at the trial investigator 
meetings
13.[ADDRESS_1020694] Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local reg ulatory  requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes
[ADDRESS_1020695] be considered a protocol 
amendment, and unless such an amendment is agreed upon by [CONTACT_275436]/IEC and health authorities, where required, it cannot be implemented.
[COMPANY_001] Confidential Page 78
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
14.[ADDRESS_1020696] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for patient safet y may be implemented immediately 
provided the health authorities are subsequently  notified by [CONTACT_37306]/I EC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.
[COMPANY_001] Confidential Page 79
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
[ADDRESS_1020697] .
Bakris GL, Agarwal R, Chan JC, et al (2015) Effect of finerenone on albuminuria in patients 
with diabetic nephropathy: a randomized clinical trial. JAMA; 314(9):884 -94.
Chalasani N, Regev A (2016) Drug -induced liver injury  in patients with preexisting chronic 
liver disease in drug development: how to identify  and manage? Gastroenterology ; 
151(6):1046-51.
de Zeeuw D, Coll B, Andress D, et al (2014) The endothelin antagonist atrasentan lowers 
residual albuminuria in patients with ty pe 2 diabetic nephropath y. J Am Soc Nephrol; 
25(5):1083-93.
American Diabetes Association (2010 ), Diabetes Care; 33 ([ADDRESS_1020698]) :62-69.
Gai Z, Chu L, Xu Z, et al (2017) Farnesoid X receptor activation protects the kidney  from 
ischemia- reperfusion damage. Sci Rep; 7:9815.
Gai Z, Gui T, Hiller C, et al (2016) Farnesoid X receptor protect s against kidney  injury  in 
uninephrectomized obese mice. J Biol Chem; 291(5):2397-411.
Gheith O, Farouk N, Nampoory  N, et al (2016) Diabetic kidney  disease: world wide 
difference of prevalence and risk factors. J Nephropharmacol; 5(1):49 -56.
Hanes R, Judge PK, Staplin N, et al (2018) Effects of Sacubitril/Valsartan v ersus Irbesartan in 
patients with chronic kidney  disea se. Circulation ; 138(15):1505 -1514
International Conference on Harmonization (2003) Post- approval safety  data management: 
definitions and standards for expedited reporting ED2 (Internet) Available from: 
<http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy /E2D/Ste
p4/E2D_Guideline.pdf> (Accessed 02 July 2018).
Inzucchi SE, Bergenstal RM, Buse JB, et al (2015) Management of hyperglycemia in type 2 
diabetes, 2015: a patient -centered approach: update to a position statement of the American 
Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care; 
38(1):140-9.
Levey  AS, Becker C, Inker LA (2015) Glomerular filtration rate and albuminuria for 
detection and staging of acute and chronic kidney disease in adults: a s ystematic review. 
JAMA; 313(8):837 -46.
Levey  AS, Stevens LA (2010) Estimating GFR using the CKD Epi[INVESTIGATOR_8849] 
(CKD -EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence 
estimates, and better risk predictions. Am J Kidney Dis; 55(4):622 -7.
Ma L , Yan M, Kong X, et al (2018) Association of EPHX2 R287Q poly morphism with 
diabetic nephropathy  in chinese t ype 2 diabetic patients. J Diabetes Res; 2786470.
Marquardt A, Al -Dabet MM, Ghosh S, et al (2017) Farnesoid X receptor agonism protects 
against diabetic tubulopathy : potential add- on therapy  for diabetic nephropathy . J Am Soc 
Nephrol; 28(11):3182 -9.
Okusa MD, Davenport A (2014) Reading between the (guide)lines --the KDIGO practice 
guideline on acute kidney injury  in the individual patient. Kidney  Int; 85(1):39 -48.
[COMPANY_001] Confidential Page 80
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Pradeepa R, Mohan V (2017) Prevalence of t ype 2 diabetes and its complications in I ndia and 
economic costs to the nation. Eur J Clin Nutr; 71(7):816-24.
Umanath K, Lewis JB (2018) Update on diabetic nephropath y: core curriculum 2018. Am J 
Kidney  Dis; 71(6):884- 95. 
Whelton PK, Carey  RM, Aronow WS, et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/ 
AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, 
and Management of High Blood Pressure in Adults: Executive Summary . Hypertension;
71:e13- e115 .
Zhang X, Huang S, Gao M, et al (2014) Farnesoid X receptor (FXR) gene deficiency  impairs 
urine concentration in mice. Proc Natl Acad Sci [LOCATION_003]; 111(6):2277 -82.
Zhao K, He J, Zhang Y, et al (2016) Activation of FXR protects against renal fibrosis via 
suppressing Smad3 expression. Sci Rep;(6):[ZIP_CODE].
[COMPANY_001] Confidential Page 81
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
16 Appendices
16.1 Appendix 1: Clinically  notabl e laboratory  values and vital signs
Please refer to the Central Laboratory  Manual for a list of clinically significant laboratory  values.
[COMPANY_001] Confidential Page 82
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
16.2 Appendix 2: Liver event and Laboratory  trigger Definitions and 
Follow -up Requirements
Table 16-1 Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER LABORATORY 
TRIGGERS[ADDRESS_1020699] < ALT / AST ≤ [ADDRESS_1020700]
1.[ADDRESS_1020701] < TBL ≤ [ADDRESS_1020702]
LIVER EVENTS ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert syndrome)
Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and
TBL > 2 × ULN [mainly conjugated fraction] without notable increase
in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue,
abdom inal pain, nausea, or vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver
neoplasms TBL: total bilirubin; ULN: upper limit of normal
Chalasani andRegev 2016
[COMPANY_001] Confidential Page 83
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Table 16-2 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law caseaDiscontinue the study 
treatment immediately
Hospi[INVESTIGATOR_18552], if clinically 
appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γ -GT until resolutionc
(frequency at investigator 
discretion)
ALT or A ST
for patients with normal 
baseline: > 8 × ULN
For patients with elevated 
baseline> [ADDRESS_1020703] or > 500 U/L 
whichever comes firstDiscontinue the study 
treatment immediately
Hospi[INVESTIGATOR_6547]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
For patients with normal 
baseline: > 5 to ≤ 8 × ULN
For patients with elevated 
baseline: >5 to ≤ [ADDRESS_1020704] or
>5X ULN to ≤ 500 U/L 
whichever comes firstRepeat LFT within 48 
hours
If elevation persists, 
continue follow -up 
monitoring
If elevation persists for 
more than 2 weeks, 
discontinue the study drug
Establish causality
Complete liver CRFALT, AST, TBL, Alb, P T/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 × ULN accompanied by 
[CONTACT_18688]Discontinue the study 
treatment immediately
Hospi[INVESTIGATOR_6547]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 to ≤ 5 × ULN (patient is 
asymptomatic)Repeat LFT within the next 
week
If elevation is confirmed, 
initiate close observation 
of the patientInvestigator discretion
Monitor LF T within 1 to 4 
weeks
ALP (isolated)
> 2 × ULN (in the absence of 
known bone pathology)Repeat LFT within 48 
hours
If elevation persists, 
establish causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
TBL (isolated)
[COMPANY_001] Confidential Page 84
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
Criteria Actions required Follow -up monitoring
> 2 × ULN (in the absence of
known Gilbert syndrome)Repeat LFT within 48
hours
If elevation persists,
discontinue the study drug
immediately
Hospi[INVESTIGATOR_275406]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
Test for hemoly sis (e.g., 
reticulocytes, haptoglobin, 
unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN (patient is
asymptomatic)Repeat LFT within the next
week
If elev ation is confirmed,
initiate close observation
of the patientInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
Jaundice Discontinue the study
treatment immediately
Hospi[INVESTIGATOR_18554]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
Any AE potentially indicative of 
a liver toxicity*Consider study treatment
interruption or
discontinuation
Hospi[INVESTIGATOR_275407]
Establish ca usality
Complete liver CRFInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN 
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level 
after a maximum of 6 months, (4) liver transplantation, and (5) death .
Chalasani andRegev 2016
[COMPANY_001] Confidential Page 85
Amended Protocol Version v 03 (Clean ) Protocol No. CLMB763X2202
16.3 Appendix 3: Specific Renal A lert Criteria and A ctions and Event 
Follow -up
Table 16-3 Specific Renal A lert Criteria and A ctions
Serum Event
Serum creatinine increase 25 –49% compared to 
baselineConfirm 25% increase after 24- 48h
Follow up within 2 -5 days
Acute Kidney Injury: Serum creatinine increase 50% 
compared to baselineFollow up within 24 -48h if possible
Consider study treatment interruption
Consider patient hospi[INVESTIGATOR_059] /specialized 
treatment
Urine Event
Albumin -creatinine ratio increase ≥2 fold from 
baseline valueConfirm value after 24- 48h
Perform urine microscopy
Consider study treatment interruption / or 
discontinuation
Blood glucose (fasting)
Perform serum creatinine, UACR
New dipstick hematuria ≥1+ not due to trauma Urine sediment microscopy
Perform serum creatinine, UACR
For all renal events:
Document contributing factors in the CRF: co -medication, other co -morbid conditions, and additional 
diagnostic procedures performed
Monitor patient regularly (frequency at investigator’s discretion) until either:
Event resolution: sCr within 10% of baseline or albumin -creatinine ratio within 50% of baseline, or
Event stabilization: sCr level with ±10% variability over last 6 months or albumin -creatinine ratio 
stabilization at a new level with ±50% variability over last 6 months.
Bakris et al 2015 , deZeeuw etal2014